<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:11:41Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10421951" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10421951</identifier>
        <datestamp>2023-08-13</datestamp>
        <setSpec>brjcancer</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
              <journal-id journal-id-type="iso-abbrev">Br J Cancer</journal-id>
              <journal-title-group>
                <journal-title>British Journal of Cancer</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0007-0920</issn>
              <issn pub-type="epub">1532-1827</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10421951</article-id>
              <article-id pub-id-type="pmcid">PMC10421951</article-id>
              <article-id pub-id-type="pmc-uid">10421951</article-id>
              <article-id pub-id-type="pmid">37420000</article-id>
              <article-id pub-id-type="pmid">37420000</article-id>
              <article-id pub-id-type="publisher-id">2310</article-id>
              <article-id pub-id-type="doi">10.1038/s41416-023-02310-1</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Joharatnam-Hogan</surname>
                    <given-names>Nalinie</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Hatem</surname>
                    <given-names>Duaa</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cafferty</surname>
                    <given-names>Fay H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Petrucci</surname>
                    <given-names>Giovanna</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2717-7979</contrib-id>
                  <name>
                    <surname>Cameron</surname>
                    <given-names>David A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1230-2973</contrib-id>
                  <name>
                    <surname>Ring</surname>
                    <given-names>Alistair</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kynaston</surname>
                    <given-names>Howard G.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gilbert</surname>
                    <given-names>Duncan C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff35">35</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8018-7730</contrib-id>
                  <name>
                    <surname>Wilson</surname>
                    <given-names>Richard H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hubner</surname>
                    <given-names>Richard A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6186-5759</contrib-id>
                  <name>
                    <surname>Swinson</surname>
                    <given-names>Daniel E. B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1741-478X</contrib-id>
                  <name>
                    <surname>Cleary</surname>
                    <given-names>Siobhan</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Robbins</surname>
                    <given-names>Alex</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>MacKenzie</surname>
                    <given-names>Mairead</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Scott-Brown</surname>
                    <given-names>Martin W. G.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff13">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sothi</surname>
                    <given-names>Sharmila</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff13">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dawson</surname>
                    <given-names>Lesley K.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff14">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Capaldi</surname>
                    <given-names>Lisa M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff15">15</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Churn</surname>
                    <given-names>Mark</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff15">15</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5158-1069</contrib-id>
                  <name>
                    <surname>Cunningham</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Khoo</surname>
                    <given-names>Vincent</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Armstrong</surname>
                    <given-names>Anne C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ainsworth</surname>
                    <given-names>Nicola L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff16">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Horan</surname>
                    <given-names>Gail</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff16">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wheatley</surname>
                    <given-names>Duncan A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff17">17</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mullen</surname>
                    <given-names>Russell</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff18">18</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6268-6015</contrib-id>
                  <name>
                    <surname>Lofts</surname>
                    <given-names>Fiona J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff19">19</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Walther</surname>
                    <given-names>Axel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff20">20</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Herbertson</surname>
                    <given-names>Rebecca A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff21">21</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Eaton</surname>
                    <given-names>John D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff22">22</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>O’Callaghan</surname>
                    <given-names>Ann</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff23">23</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Eichholz</surname>
                    <given-names>Andrew</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff24">24</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kagzi</surname>
                    <given-names>Mohammed M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff25">25</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Patterson</surname>
                    <given-names>Daniel M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff26">26</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Narahari</surname>
                    <given-names>Krishna</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff27">27</xref>
                  <xref ref-type="aff" rid="Aff28">28</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bradbury</surname>
                    <given-names>Jennifer</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff29">29</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stokes</surname>
                    <given-names>Zuzana</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff30">30</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rizvi</surname>
                    <given-names>Azhar J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff31">31</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Walker</surname>
                    <given-names>Georgina A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff32">32</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kunene</surname>
                    <given-names>Victoria L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff33">33</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Srihari</surname>
                    <given-names>Narayanan</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff34">34</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gentry-Maharaj</surname>
                    <given-names>Aleksandra</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7962-964X</contrib-id>
                  <name>
                    <surname>Meade</surname>
                    <given-names>Angela</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Patrono</surname>
                    <given-names>Carlo</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rocca</surname>
                    <given-names>Bianca</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9706-016X</contrib-id>
                  <name>
                    <surname>Langley</surname>
                    <given-names>Ruth E.</given-names>
                  </name>
                  <address>
                    <email>ruth.langley@ucl.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.415052.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0606 323X</institution-id><institution>MRC Clinical Trials Unit, UCL, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.8142.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0941 3192</institution-id><institution>Department of Safety and Bioethics, Division of Pharmacology, </institution><institution>Catholic University School of Medicine, </institution></institution-wrap>Rome, Italy </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.18886.3f</institution-id><institution>The Institute of Cancer Research, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.417068.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0624 9907</institution-id><institution>Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, </institution><institution>The University of Edinburgh, Western General Hospital, </institution></institution-wrap>Edinburgh, UK </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.5072.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0304 893X</institution-id><institution>The Royal Marsden NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.5600.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 5670</institution-id><institution>Department of Urology, </institution><institution>Cardiff University School of Medicine, </institution></institution-wrap>Cardiff, UK </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.8756.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2193 314X</institution-id><institution>School of Cancer Sciences, </institution><institution>University of Glasgow, </institution></institution-wrap>Glasgow, UK </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.422301.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0606 0717</institution-id><institution>The Beatson West of Scotland Cancer Centre, </institution></institution-wrap>Glasgow, UK </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.412917.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0430 9259</institution-id><institution>The Christie NHS Foundation Trust, Department of Medical Oncology, </institution></institution-wrap>Manchester, UK </aff>
                <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.5379.8</institution-id><institution-id institution-id-type="ISNI">0000000121662407</institution-id><institution>University of Manchester, Division of Cancer Sciences, </institution></institution-wrap>Manchester, UK </aff>
                <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.415967.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9965 1030</institution-id><institution>Leeds Teaching Hospitals NHS Trust, </institution></institution-wrap>Leeds, UK </aff>
                <aff id="Aff12"><label>12</label>Independent Cancer Patients’ Voice, London, UK </aff>
                <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.15628.38</institution-id><institution-id institution-id-type="ISNI">0000 0004 0393 1193</institution-id><institution>University Hospitals Coventry and Warwickshire NHS Trust, </institution></institution-wrap>Coventry, UK </aff>
                <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.417068.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0624 9907</institution-id><institution>Edinburgh Cancer Centre, Western General Hospital, </institution></institution-wrap>Edinburgh, UK </aff>
                <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.430729.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0486 7170</institution-id><institution>Worcestershire Acute Hospitals NHS Trust, </institution></institution-wrap>Worcester, UK </aff>
                <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.470208.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0415 9545</institution-id><institution>The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust, </institution></institution-wrap>King’s Lynn, UK </aff>
                <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.412944.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0474 4488</institution-id><institution>Royal Cornwall Hospitals NHS Trust, </institution></institution-wrap>Cornwall, UK </aff>
                <aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.412942.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1795 1910</institution-id><institution>The Highland Breast Centre, Raigmore Hospital, </institution></institution-wrap>Inverness, UK </aff>
                <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.451349.e</institution-id><institution>St George’s University Hospitals NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="GRID">grid.410421.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0380 7336</institution-id><institution>University Hospitals Bristol and Weston NHS Foundation Trust, </institution></institution-wrap>Bristol, UK </aff>
                <aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="GRID">grid.511096.a</institution-id><institution>University Hospitals Sussex NHS Foundation Trust, </institution></institution-wrap>Brighton, UK </aff>
                <aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="GRID">grid.488594.c</institution-id><institution-id institution-id-type="ISNI">0000000404156862</institution-id><institution>University Hospitals of Morecambe Bay NHS Foundation Trust, </institution></institution-wrap>Kendal, UK </aff>
                <aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="GRID">grid.418709.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0456 1761</institution-id><institution>Portsmouth Hospitals University NHS Trust, </institution></institution-wrap>Portsmouth, UK </aff>
                <aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="GRID">grid.439664.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 863X</institution-id><institution>Buckinghamshire Healthcare NHS Trust, </institution></institution-wrap>Buckinghamshire, UK </aff>
                <aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="GRID">grid.440194.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 4647 6776</institution-id><institution>South Tees Hospitals NHS Foundation Trust, </institution></institution-wrap>Middlesbrough, UK </aff>
                <aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="GRID">grid.440202.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0575 1944</institution-id><institution>West Suffolk Hospitals NHS Trust, </institution></institution-wrap>St Edmunds, UK </aff>
                <aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="GRID">grid.241103.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0169 7725</institution-id><institution>University Hospital of Wales, Cardiff and Vale University Health Board, </institution></institution-wrap>Cardiff, UK </aff>
                <aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="GRID">grid.5600.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 5670</institution-id><institution>Division of Cancer and Genetics, </institution><institution>Cardiff University, </institution></institution-wrap>Cardiff, UK </aff>
                <aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="GRID">grid.419439.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0460 7002</institution-id><institution>Salisbury NHS Foundation Trust, </institution></institution-wrap>Salisbury, UK </aff>
                <aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="GRID">grid.433807.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0642 1066</institution-id><institution>United Lincolnshire Hospitals NHS Trust, </institution></institution-wrap>Lincoln City, UK </aff>
                <aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="GRID">grid.415667.7</institution-id><institution>Milton Keynes University Hospital NHS Foundation Trust, </institution></institution-wrap>Milton Keynes, UK </aff>
                <aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="GRID">grid.240404.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0440 1889</institution-id><institution>Nottingham University Hospitals NHS Trust, </institution></institution-wrap>Nottingham, UK </aff>
                <aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="GRID">grid.412563.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0376 6589</institution-id><institution>Walsall Manor Hospital and University Hospitals, Birmingham NHS Foundation Trust, </institution></institution-wrap>Birmingham, UK </aff>
                <aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="GRID">grid.439417.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0472 4225</institution-id><institution>Shrewsbury and Telford Hospital NHS Trust, </institution></institution-wrap>Shrewsbury, UK </aff>
                <aff id="Aff35"><label>35</label><institution-wrap><institution-id institution-id-type="GRID">grid.511096.a</institution-id><institution>Present Address: University Hospitals Sussex NHS Foundation Trust, </institution></institution-wrap>Brighton, UK </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>7</day>
                <month>7</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>7</day>
                <month>7</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <day>7</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <volume>129</volume>
              <issue>4</issue>
              <fpage>706</fpage>
              <lpage>720</lpage>
              <history>
                <date date-type="received">
                  <day>31</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
                <date date-type="rev-recd">
                  <day>9</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>5</day>
                  <month>6</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">Pre-clinical models demonstrate that platelet activation is involved in the spread of malignancy. Ongoing clinical trials are assessing whether aspirin, which inhibits platelet activation, can prevent or delay metastases.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">Urinary 11-dehydro-thromboxane B<sub>2</sub> (U-TXM), a biomarker of in vivo platelet activation, was measured after radical cancer therapy and correlated with patient demographics, tumour type, recent treatment, and aspirin use (100 mg, 300 mg or placebo daily) using multivariable linear regression models with log-transformed values.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">In total, 716 patients (breast 260, colorectal 192, gastro-oesophageal 53, prostate 211) median age 61 years, 50% male were studied. Baseline median U-TXM were breast 782; colorectal 1060; gastro-oesophageal 1675 and prostate 826 pg/mg creatinine; higher than healthy individuals (~500 pg/mg creatinine). Higher levels were associated with raised body mass index, inflammatory markers, and in the colorectal and gastro-oesophageal participants compared to breast participants (<italic>P</italic> &lt; 0.001) independent of other baseline characteristics. Aspirin 100 mg daily decreased U-TXM similarly across all tumour types (median reductions: 77–82%). Aspirin 300 mg daily provided no additional suppression of U-TXM compared with 100 mg.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p id="Par4">Persistently increased thromboxane biosynthesis was detected after radical cancer therapy, particularly in colorectal and gastro-oesophageal patients. Thromboxane biosynthesis should be explored further as a biomarker of active malignancy and may identify patients likely to benefit from aspirin.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Cancer</kwd>
                <kwd>Cancer</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000289</institution-id>
                      <institution>Cancer Research UK (CRUK)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>C471/A19252</award-id>
                  <award-id>C569/A24991</award-id>
                  <award-id>C471/A15015</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Langley</surname>
                      <given-names>Ruth E.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000272</institution-id>
                      <institution>DH | National Institute for Health Research (NIHR)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>12/01/38</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Langley</surname>
                      <given-names>Ruth E.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000265</institution-id>
                      <institution>RCUK | Medical Research Council (MRC)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>MC_UU_00004/02</award-id>
                  <award-id>MC_UU_12023/28</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Langley</surname>
                      <given-names>Ruth E.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Springer Nature Limited 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Introduction</title>
              <p id="Par5">Activated platelets play a central role in the development and spread of cancer, as well as in haemostasis and thrombosis, tissue repair, and inflammation [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>]. The association of platelets with malignancy was highlighted by Trousseau in 1865 with the observation that thrombosis could be an early sign of occult malignancy [<xref ref-type="bibr" rid="CR4">4</xref>]. Pre-clinical experimental models demonstrate the interaction between platelets, circulating tumour cells, the tumour microenvironment and the development of metastases (reviewed in refs. [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]). Activated platelets are thought to protect circulating tumour cells from immune clearance, promote adhesion to the endothelium, facilitate transendothelial migration and the formation of metastatic niches.</p>
              <p id="Par6">The primary effect of once-daily low-dose (75–100 mg) aspirin is the irreversible acetylation of cyclo-oxygenase-1 (COX-1) in platelets [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Thromboxane A<sub>2</sub> (TXA<sub>2</sub>) is the main product of platelet arachidonic acid metabolism via COX-1, and amplifies platelet activation and aggregation in response to various stimuli [<xref ref-type="bibr" rid="CR10">10</xref>]. Inhibition of COX-1 in platelets with aspirin, or abolition of TXA<sub>2</sub> signalling by either genetic or pharmacological manipulation, in pre-clinical models, leads to a reduction in metastases attributed to an effect on circulating tumour cells and their interaction with platelets during intravascular transition [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p>
              <p id="Par7">The link between TXA<sub>2</sub>-dependent platelet activation and increased COX-2 expression which is associated with carcinogenesis [<xref ref-type="bibr" rid="CR13">13</xref>] has been strengthened by recent data obtained from genetically modified mice. Mice with a specific deletion of COX-1 in megakaryocytes/platelets (pPtgs1<sup>−/−</sup>) were crossed with Apc<sup>min/+</sup> mice which develop multiple intestinal polyps and are considered a relevant model for studying intestinal carcinogenesis. The pPtgs1<sup>−/−</sup>/Apc<sup>min/+</sup> mice with largely suppressed TXA<sub>2</sub> biosynthesis developed significantly fewer intestinal adenomas than Apc<sup>min/+</sup> mice, and the adenomas that did develop had a lower proliferative index and reduced COX-2 expression. This data suggests that the role of COX-1 in platelets in terms of promoting intestinal carcinogenesis could be mediated through the release of pro-inflammatory and pro-angiogenic autacoids to enhance aberrant adenomatous COX-2 expression [<xref ref-type="bibr" rid="CR14">14</xref>]. Data have also shown an association between overexpression of TXA<sub>2</sub> synthase and TXA<sub>2</sub> receptors in multiple cancer types [<xref ref-type="bibr" rid="CR15">15</xref>], as well as an unexpected association between a single nucleotide polymorphism in TBXA<sub>2</sub> receptor, causing a gain in function, and a multiple metastatic phenotype across tumour types [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
              <p id="Par8">Epidemiological and randomised data demonstrate that once-daily aspirin use reduces cancer incidence particularly for tumours that arise from the gastrointestinal tract [<xref ref-type="bibr" rid="CR17">17</xref>–<xref ref-type="bibr" rid="CR20">20</xref>], and when individuals are at increased risk of developing malignancy. For example, aspirin has recently been recommended by the UK National Institute for Clinical Excellence (NICE) for the prevention of colorectal cancer in Lynch Syndrome (hereditary mismatch repair deficiency (MMRd)) [<xref ref-type="bibr" rid="CR21">21</xref>] as a result of long-term data from the CAPP2 trial (ISCRTN59521990) [<xref ref-type="bibr" rid="CR22">22</xref>]. Beyond this however, there is still uncertainty as to how aspirin can be best employed in the anti-cancer armamentarium. For primary prevention in the wider population, there are concerns about potential benefits being outweighed by the bleeding risk from aspirin [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. For the treatment of cancer/prevention of metastases, there are several randomised trials ongoing internationally to assess whether aspirin use after initial radical treatment, particularly for colorectal cancer, can prevent or delay the subsequent formation of metastases [<xref ref-type="bibr" rid="CR25">25</xref>].</p>
              <p id="Par9">It is estimated that about 5% of patients who present with unexplained venous thromboembolism (VTE) develop cancer within 1 year of diagnosis. The risk of developing a cancer-associated VTE depends on the type and stage of the cancer, treatment received, as well as the underlying risk of the patient [<xref ref-type="bibr" rid="CR26">26</xref>]. Several biomarkers of haemostasis for example d-dimer appear to be associated with VTE and cancer progression [<xref ref-type="bibr" rid="CR27">27</xref>]. Clinical markers of platelet activation (for example soluble P-selectin) have also been shown to be associated with the development of thromboses in cancer patients [<xref ref-type="bibr" rid="CR28">28</xref>]. In a cohort of 687 cancer patients (35% newly diagnosed with localised disease) the probability of a VTE during the first 6 months of the study was 11.9% for those with a serum P-selectin above the 75th percentile and 3.7% for those below [<xref ref-type="bibr" rid="CR29">29</xref>]. However, in this study other markers of platelet activation (soluble CD40 ligand, thrombospondin-1 (TSP-1) and platelet factor-4 (PF-4)) were not associated with VTE, and haemostatic biomarkers are not routinely measured in oncological practice.</p>
              <p id="Par10">TXA<sub>2</sub> is chemically unstable in aqueous solution with a very short half-life ~30 s [<xref ref-type="bibr" rid="CR30">30</xref>]. It hydrolyses non-enzymatically to the inactive, but chemically stable, urinary 11-dehydro-thromboxane B<sub>2</sub> (U-TXM) a major enzymatic metabolite of TXA<sub>2</sub>/TXB<sub>2</sub> [<xref ref-type="bibr" rid="CR31">31</xref>]. U-TXM provides a non-invasive index or biomarker of in vivo TXA<sub>2</sub> biosynthesis. U-TXM has been used extensively to characterise clinical scenarios associated with enhanced platelet activation within the fields of cardiology and onco-haematology, and to guide the design of low-dose aspirin trials in these settings [<xref ref-type="bibr" rid="CR31">31</xref>–<xref ref-type="bibr" rid="CR33">33</xref>]. More recently, high excretion rates of U-TXM in a cohort of the Framingham Heart Study (<italic>n</italic> = 3044) have been associated with increased cancer mortality (hazard ratio (HR) 1.63, 95% confidence interval (CI) 1.24–2.13, <italic>P</italic> = 0.0005), as well as cardiovascular mortality (HR 2.41, 95% CI 1.71–3.39, <italic>P</italic> &lt; 0.0001) and all-cause mortality (HR 1.96, 95% CI 1.68–2.29, <italic>P</italic> &lt; 0.0001) [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
              <p id="Par11">Further understanding of the mechanism(s) underlying the anti-cancer effects of aspirin would permit a more nuanced and precision-medicine approach to the use of aspirin in the field of oncology. The ongoing adjuvant Add-Aspirin trial (ISRCTN74358648) which is evaluating the effect of aspirin use after radical treatment in four different tumour types and evaluating 2 different doses of aspirin, provided an opportunity to further study thromboxane biosynthesis in cancer patients at an early stage of their disease, and the short-term effects of two doses aspirin. The specific aims of this study were: (i) to examine the levels of thromboxane biosynthesis using U-TXM as a biomarker in cancer patients who had recently completed radical treatment and had no radiological or standard clinical evidence of metastatic disease, (ii) to evaluate the effects of aspirin 100 and 300 mg daily on U-TXM in this cohort and (iii) to provide information about participant treatment compliance in this blinded placebo-controlled trial particularly as aspirin is also available as an over-the-counter preparation.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <sec id="Sec3">
                <title>Trial design and participants</title>
                <p id="Par12">This thromboxane biosynthesis study was embedded within the randomised Add-Aspirin trial framework. The Add-Aspirin protocol encompasses four individually powered, Phase III, adjuvant studies in four different tumour types, i.e., breast, colorectal, gastro-oesophageal and prostate. Full details of the trial have been published previously [<xref ref-type="bibr" rid="CR35">35</xref>]. At trial entry, all participants start an open-label 8-week run-in phase of aspirin 100 mg daily to assess tolerability followed by random allocation to aspirin 100 mg, aspirin 300 mg or matched placebo for up to 5 years. Participants ≥75 years are only allocated to aspirin 100 mg or placebo. The timing of entry into the trial is tumour cohort-specific and dependent upon the radical treatment received. For those that had only received surgery the run-in phase could be started 6–12 weeks after surgery (and up to 16 weeks post-surgery for gastro-oesophageal cancer participants). Adjuvant chemotherapy could be ongoing at trial entry in the colorectal and gastro-oesophageal cohorts, and ongoing long-term hormonal treatment is permitted in the breast and prostate cohorts. The main exclusion criteria include regular aspirin use within the previous 5 years and concomitant medication/previous medical history that would increase the risk of aspirin toxicity.</p>
                <p id="Par13">All participants (<italic>n</italic> = 716) in this sub-study had histologically confirmed adenocarcinoma (except four participants had squamous cell histology and one adenosquamous in the gastro-oesophageal cohort). At study entry, all participants had no previous or current evidence of metastatic disease with the exception of four patients in the colorectal cohort who had completely resected liver metastases. The specific eligibility criteria for each tumour cohort were designed to identify patients who had received treatment with radical intent but were at moderate to high risk of relapse. For breast participants who had not received neoadjuvant chemotherapy the final histology had to include lymph node positivity or, if node-negative, have at least two high-risk features (defined as: oestrogen receptor (ER) negative, human epidermal growth factor receptor 2 (HER2) positive, grade 3, lymphovascular invasion present, age &lt;35 years, oncotype dx score &gt;25 or prosignia score prediction analysis of microarray 50 (PAM50) &gt; 60). Participants who received neoadjuvant chemotherapy or radiotherapy should not have achieved a complete pathological response and be either (i) HER2 positive, (ii) HER2 negative and grade 3 or (iii) HER2 negative and ER-negative. Colorectal cancer participants were eligible if, following a surgical resection, they had a pathological Stage II (T3-4 N0) or Stage III (T1-4 N1 or N2) tumour. For those that received neoadjuvant therapy (<italic>n</italic> = 8), staging is based on pre-treatment assessments. Gastro-oesophageal participants had to have undergone surgery with radical intent with a post-operative pathological stage of T1b-T4, N any, M0, or received radical radiotherapy. Prostate cancer participants were node-negative with a clinical or radiological Stage 1-3b and D’Amico classification intermediate risk (at least 1 of prostate-specific antigen [PSA] between 10 and 20, Gleason score of 7 or clinical stage T2b) or high risk (PSA &gt;20, or Gleason score &gt;8 or clinical stage T2c-3a).</p>
                <p id="Par14">The trial protocol, including the thromboxane biosynthesis study, was approved by South Central-Oxford C research ethics committee (Ref: 14/SC/0171) and by local research and development departments at all centres. Participants provided written informed consent.</p>
              </sec>
              <sec id="Sec4">
                <title>U-TXM study</title>
                <p id="Par15">The thromboxane biosynthesis study was undertaken at 28 UK centres. Participants provided 6-ml urine samples at trial entry/baseline (off aspirin), after the 8-week run-in period of aspirin 100 mg daily (24 h after the previous aspirin dose), and a third sample between 3 and 6 months after randomisation to blinded treatment (aspirin 100 mg, aspirin 300 mg or matched placebo) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) using a minimisation algorithm with a random element.<fig id="Fig1"><label>Fig. 1</label><caption><title>U-TXM study.</title><p>Urine samples were collected at trial entry (off aspirin), after an 8-week run-in period of aspirin 100 mg daily for all participants and 3–6 months after random allocation to aspirin 100 mg, aspirin 300 mg or matched placebo daily.</p></caption><graphic xlink:href="41416_2023_2310_Fig1_HTML" id="d32e1232"/></fig></p>
                <p id="Par16">End of run-in, and post-randomisation, urine samples were only included in this analysis if the participant had remained on allocated treatment. Adherence was assessed by participant self-reporting and review of used blister packs/completion of diary cards at the end of the run-in period. Based on these assessments participants were included if they had taken 6–7 tablets per week and had not discontinued treatment prior to the urine sample being obtained.</p>
                <p id="Par17">Urine samples were sent by post from trial centres to one of two trial biobanks in the UK within 24 h of collection. Aliquoted into 2-ml cryo-vials, frozen at −20 °C or below and transferred on dry ice to the Institute of Pharmacology at the Catholic University School of Medicine (Rome, Italy). The extraction procedure was performed on 1 ml urine samples as described in detail in Supplementary Appendix S<xref rid="MOESM1" ref-type="media">1</xref> and [<xref ref-type="bibr" rid="CR36">36</xref>]. U-TXM was measured with a standard Enzyme-Linked Immunosorbent Assay (ELISA) [<xref ref-type="bibr" rid="CR36">36</xref>–<xref ref-type="bibr" rid="CR38">38</xref>]; 96-well plates were coated with commercial monoclonal anti-rabbit IgG antibodies (Cayman Chemical, Ann Arbor, MI, USA) and U-TXM assessed with a standard acetylcholinesterase ELISA immunometric method using a specific rabbit polyclonal antibody. The cross-reactivity of the anti-11-dehydro-TXB<sub>2</sub> antibody against other prostanoids that can be measured in urine, namely PGE<sub>2,</sub> TXB<sub>2</sub>, 6-keto PGF<sub>1alpha</sub>, and the isoprostane 8-iso-PGF<sub>2alpha</sub> was &lt;0.05% [<xref ref-type="bibr" rid="CR39">39</xref>]. We also tested cross-reactivity with 2,3-dinor-TXB2 which was &lt;1.5% (data not shown). Results were expressed per milligram of urinary creatinine measured with a commercial kit (Creatinine Colorimetric Detection Kit; Enzo Life Sciences, Farmingdale, NY, USA). The authors involved in U-TXM measurements (DH, GP and BR) were blinded to all clinical details and aspirin/placebo allocation.</p>
              </sec>
              <sec id="Sec5">
                <title>Statistical analysis</title>
                <p id="Par18">For the breast, colorectal and prostate cohorts with a sample size of ~200 for each cohort the study was powered to estimate the baseline mean U-TXM with a precision of +/− 40 pg/mg creatinine with a 95% CI based on the U-TXM distribution of healthy individuals (mean 504 pg/mg, standard deviation 267 pg/mg) [<xref ref-type="bibr" rid="CR31">31</xref>]. For the gastro-oesophageal cohort where the sample size was smaller (<italic>n</italic> = 53) the expected precision was +/− 75 pg/mg based on a 95% CI. The primary outcomes of the analysis were to (i) estimate thromboxane biosynthesis following radical cancer therapy (at baseline); and (ii) establish the effects of daily aspirin at 100 mg and 300 mg on this parameter.</p>
                <p id="Par19">Correlations between U-TXM levels and baseline subject demographics including age, male/female, weight as body mass index (BMI), tumour type, comorbidity, smoking status, concurrent medication, recent/ongoing cancer treatment, risk of recurrence, baseline blood counts including platelet number and inflammatory markers were explored. A higher risk of recurrence was defined for each tumour cohort based on American Joint Committee on Cancer (AJCC) TNM staging (7th edition) as follows: breast Stage III (Tany N2, T3 N1-2, T4 Nany), colorectal Stage III (Tany N1-2) or Stage IV, gastro-oesophageal Stage IIB or III and for prostate cancer D’Amico high risk as previously defined. Summary statistics and plots explored associations, then linear regression models were fitted. Regression models were based on log-transformed values of U-TXM to optimise model fit. Univariable models were fitted initially, then a multivariable model was constructed using forward stepwise procedures considering all of the covariates listed (<italic>P</italic> value to enter a term &lt;0.05; <italic>P</italic> value ≥ 0.1 to remove a term). Interactions were considered, though power was low for this.</p>
                <p id="Par20">Summary statistics were used to consider U-TXM values at the end of the run-in period (by tumour cohort) and after 3 months of randomised treatment (by treatment allocation). Participants ≥75 years were not included in the analysis of dose as they were not eligible for random allocation to the higher aspirin dose. End of run-in U-TXM (adjusted for baseline values) was considered according to baseline characteristics and previous therapy in univariable and multivariable linear models (based on log-transformed U-TXM values). U-TXM during randomised treatment is presented according to the treatment group and baseline factors, but modelling was not performed due to small numbers.</p>
              </sec>
            </sec>
            <sec id="Sec6" sec-type="results">
              <title>Results</title>
              <p id="Par21">Between May 2018 and January 2021, 716 participants provided a urine sample at trial entry with the number of follow-up samples shown in the consort diagram (Supplementary Appendix S<xref rid="MOESM1" ref-type="media">2</xref>). The number of participants in each tumour cohort (including the proportion not proceeding from run-in to randomisation (12% in this study and 15% in the trial overall), and the baseline characteristics (Table <xref rid="Tab1" ref-type="table">1A</xref>) were in line with the trial more broadly [<xref ref-type="bibr" rid="CR40">40</xref>]. The median age of the whole cohort was 61 years with the expected male: female ratio within each tumour type, 27% with a BMI ≥ 30 kg/m<sup>2</sup>, 42% previous and 5% current smokers. Details of the radical treatment received are also in Table <xref rid="Tab1" ref-type="table">1A</xref>. Thirty-five percent had just received surgery (most common in the prostate cohort), 49% had undergone surgery followed by adjuvant chemotherapy and 14% radical radiotherapy or chemoradiation. Twenty-one percent were within 6–12 weeks of surgery and for only 17 (2%) was the adjuvant chemotherapy still ongoing.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Participant demographics and baseline U-TXM data. Panel A: participant characteristics and panel B: U-TXM at trial registration cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="6">(A)</th></tr><tr><th/><th>Breast</th><th>Colorectal</th><th>Gastro-oesophageal</th><th>Prostate</th><th>All</th></tr></thead><tbody><tr><td>Number of participants</td><td>260</td><td>192</td><td>53</td><td>211</td><td>716</td></tr><tr><td colspan="6"><bold>Gender</bold></td></tr><tr><td> Male</td><td>1, &lt;1%</td><td>104, 54%</td><td>40, 75%</td><td>211, 100%</td><td>356, 50%</td></tr><tr><td> Female</td><td>259, &gt;99%</td><td>88, 46%</td><td>13, 25%</td><td>0, 0%</td><td>360, 50%</td></tr><tr><td colspan="6"><bold>Age at registration (years)</bold></td></tr><tr><td> Median (IQR)</td><td>53 (47–62)</td><td>61 (52–69)</td><td>63 (58–69)</td><td>67 (62–72)</td><td>61 (52–68)</td></tr><tr><td> Range</td><td>25–80</td><td>21–81</td><td>43–79</td><td>48–83</td><td>21–83</td></tr><tr><td> Under 50 years</td><td>88, 34%</td><td>34, 18%</td><td>6, 11%</td><td>1, &lt;1%</td><td>129, 18%</td></tr><tr><td> 50–59 years</td><td>94, 36%</td><td>53, 28%</td><td>13, 25%</td><td>32, 15%</td><td>192, 27%</td></tr><tr><td> 60–69 years</td><td>58, 22%</td><td>59, 31%</td><td>21, 40%</td><td>108, 51%</td><td>246, 34%</td></tr><tr><td> 70 years or older</td><td>20, 8%</td><td>46, 24%</td><td>13, 25%</td><td>70, 33%</td><td>149, 21%</td></tr><tr><td colspan="6"><bold>BM</bold><bold>I</bold></td></tr><tr><td> Median (Q1–Q3)</td><td>27 (24–32)</td><td>27 (24–31)</td><td>25 (23–29)</td><td>28 (25–31)</td><td>27 (24–31)</td></tr><tr><td> Range</td><td>18–45</td><td>19–47</td><td>16–33</td><td>20–45</td><td>16–47</td></tr><tr><td> Missing</td><td>21</td><td>13</td><td>7</td><td>11</td><td>52</td></tr><tr><td> Under 25</td><td>79, 30%</td><td>58, 30%</td><td>22, 42%</td><td>44, 21%</td><td>203, 28%</td></tr><tr><td> 25–29.9</td><td>80, 31%</td><td>71, 37%</td><td>17, 32%</td><td>97, 46%</td><td>265, 37%</td></tr><tr><td> 30–34.9</td><td>42, 16%</td><td>34, 18%</td><td>7, 13%</td><td>41, 19%</td><td>124, 17%</td></tr><tr><td> 35 or more</td><td>38, 15%</td><td>16, 8%</td><td>0, 0%</td><td>18, 9%</td><td>72, 10%</td></tr><tr><td> Missing</td><td>21, 8%</td><td>13, 7%</td><td>7, 13%</td><td>11, 5%</td><td>52, 7%</td></tr><tr><td colspan="6"><bold>Smoking status</bold></td></tr><tr><td> Never</td><td>154, 59%</td><td>93, 48%</td><td>19, 36%</td><td>109, 52%</td><td>375, 52%</td></tr><tr><td> Ex-smoker</td><td>94, 36%</td><td>88, 46%</td><td>30, 57%</td><td>91, 43%</td><td>303, 42%</td></tr><tr><td> Current smoker</td><td>12, 5%</td><td>11, 6%</td><td>4, 8%</td><td>11, 5%</td><td>38, 5%</td></tr><tr><td colspan="6"><bold>Diabetic</bold></td></tr><tr><td> No</td><td>232, 89%</td><td>165, 86%</td><td>44, 83%</td><td>189, 90%</td><td>630, 88%</td></tr><tr><td> Yes</td><td>5, 2%</td><td>16, 8%</td><td>6, 11%</td><td>11, 5%</td><td>38, 5%</td></tr><tr><td> Missing</td><td>23, 9%</td><td>11, 6%</td><td>3, 6%</td><td>11, 5%</td><td>48, 7%</td></tr><tr><td colspan="6"><bold>Receiving BP treatmen</bold>t</td></tr><tr><td> No</td><td>200, 77%</td><td>135, 70%</td><td>33, 62%</td><td>124, 59%</td><td>492, 69%</td></tr><tr><td> Yes</td><td>38, 15%</td><td>44, 23%</td><td>17, 32%</td><td>74, 35%</td><td>173, 24%</td></tr><tr><td> Missing</td><td>22, 8%</td><td>13, 7%</td><td>3, 6%</td><td>13, 6%</td><td>51, 7%</td></tr><tr><td colspan="6"><bold>Statins taken within the last week</bold></td></tr><tr><td> No</td><td>236, 91%</td><td>148, 77%</td><td>38, 72%</td><td>144, 68%</td><td>566, 79%</td></tr><tr><td> Yes</td><td>11, 4%</td><td>33, 17%</td><td>13, 25%</td><td>54, 26%</td><td>111, 16%</td></tr><tr><td> Missing</td><td>13, 5%</td><td>11, 6%</td><td>2, 4%</td><td>13, 6%</td><td>39, 5%</td></tr><tr><td colspan="6"><bold>Neutrophils (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> &lt;5.0</td><td>227, 87%</td><td>159, 83%</td><td>43, 81%</td><td>172, 82%</td><td>601, 84%</td></tr><tr><td> ≥5.0</td><td>20, 8%</td><td>25, 13%</td><td>8, 15%</td><td>29, 14%</td><td>82, 11%</td></tr><tr><td> Missing</td><td>13, 5%</td><td>8, 4%</td><td>2, 4%</td><td>10, 5%</td><td>33, 5%</td></tr><tr><td colspan="6"><bold>Total WCC (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> &lt;8.0</td><td>237, 91%</td><td>162, 84%</td><td>42, 79%</td><td>184, 87%</td><td>625, 87%</td></tr><tr><td> ≥8.0</td><td>9, 3%</td><td>22, 11%</td><td>9, 17%</td><td>16, 8%</td><td>56, 8%</td></tr><tr><td> Missing</td><td>14, 5%</td><td>8, 4%</td><td>2, 4%</td><td>11, 5%</td><td>35, 5%</td></tr><tr><td colspan="6"><bold>Platelet count (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> &lt;350</td><td>230, 88%</td><td>173, 90%</td><td>44, 83%</td><td>196, 93%</td><td>643, 90%</td></tr><tr><td> ≥350</td><td>13, 5%</td><td>12, 6%</td><td>7, 13%</td><td>5, 2%</td><td>37, 5%</td></tr><tr><td> Missing</td><td>17, 7%</td><td>7, 4%</td><td>2, 4%</td><td>10, 5%</td><td>36, 5%</td></tr><tr><td colspan="6"><bold>Raised LDL, total cholesterol or non-HDL</bold><sup>a</sup></td></tr><tr><td> No</td><td>70, 27%</td><td>81, 42%</td><td>31, 58%</td><td>88, 42%</td><td>270, 38%</td></tr><tr><td> Yes</td><td>154, 59%</td><td>92, 48%</td><td>18, 34%</td><td>98, 46%</td><td>362, 51%</td></tr><tr><td> Missing</td><td>36, 14%</td><td>19, 10%</td><td>4, 8%</td><td>25, 12%</td><td>84, 12%</td></tr><tr><td colspan="6"><bold>CRP result (categorised)</bold></td></tr><tr><td> ≤5</td><td>208, 80%</td><td>145, 76%</td><td>41, 77%</td><td>168, 80%</td><td>562, 78%</td></tr><tr><td> &gt;5</td><td>28, 11%</td><td>30, 16%</td><td>8, 15%</td><td>23, 11%</td><td>89, 12%</td></tr><tr><td> Missing</td><td>24, 9%</td><td>17, 9%</td><td>4, 8%</td><td>20, 9%</td><td>65, 9%</td></tr><tr><td colspan="6"><bold>Higher-risk disease</bold><sup>b</sup></td></tr><tr><td> No</td><td>183, 70%</td><td>78, 41%</td><td>10, 19%</td><td>71, 34%</td><td>342, 48%</td></tr><tr><td> Yes</td><td>66, 25%</td><td>111, 58%</td><td>42, 79%</td><td>137, 65%</td><td>356, 50%</td></tr><tr><td> Missing</td><td>11, 4%</td><td>3, 2%</td><td>1, 2%</td><td>3, 1%</td><td>18, 3%</td></tr><tr><td colspan="6"><bold>Primary treatment detail</bold><bold>s</bold></td></tr><tr><td> Surgery, no adjuvant chemo</td><td>84, 32%</td><td>44, 23%</td><td>10, 19%</td><td>112, 53%</td><td>250, 35%</td></tr><tr><td> Surgery with adjuvant chemo</td><td>166, 64%</td><td>145, 76%</td><td>39, 74%</td><td>0, 0%</td><td>350, 49%</td></tr><tr><td> Radical RT or CRT</td><td>0, 0%</td><td>0, 0%</td><td>3, 6%</td><td>97, 46%</td><td>100, 14%</td></tr><tr><td> Missing details (surgery pts)</td><td>10, 4%</td><td>3, 2%</td><td>1, 2%</td><td>2, &lt;1%</td><td>16, 2%</td></tr><tr><td colspan="6"><bold>Weeks between surgery and registration (n = 616)</bold><sup>c</sup></td></tr><tr><td> 6–12 weeks</td><td>12, 5%</td><td>42, 22%</td><td>9, 17%</td><td>90, 43%</td><td>153, 21%</td></tr><tr><td> &gt;12 weeks</td><td>233, 90%</td><td>143, 74%</td><td>40, 75%</td><td>20, 9%</td><td>436, 61%</td></tr><tr><td> Missing</td><td>15, 6%</td><td>7, 4%</td><td>1, 2%</td><td>4, 2%</td><td>27, 4%</td></tr><tr><td colspan="6"><bold>Timing of entry relative to adjuvant chemotherapy (n = 366)</bold></td></tr><tr><td> After chemo has finished</td><td>166, 64%</td><td>129, 67%</td><td>38, 72%</td><td>0, 0%</td><td>333, 47%</td></tr><tr><td> While chemo is ongoing</td><td>0, 0%</td><td>16, 8%</td><td>1, 2%</td><td>0, 0%</td><td>17, 2%</td></tr><tr><td> Missing</td><td>10, 4%</td><td>3, 2%</td><td>1, 2%</td><td>2, &lt;1%</td><td>16, 2%</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="5">(B)</th></tr><tr><th>Baseline characteristic</th><th><italic>n</italic></th><th>Median</th><th>(Q1, Q3)</th><th>[Range]</th></tr></thead><tbody><tr><td colspan="5"><bold>Tumour type</bold></td></tr><tr><td> Breast</td><td>260</td><td>782</td><td>(503, 1178)</td><td>[114, 5999]</td></tr><tr><td> Colorectal</td><td>192</td><td>1060</td><td>(667, 1558)</td><td>[159, 5159]</td></tr><tr><td> Gastro-oesophageal</td><td>53</td><td>1675</td><td>(1150, 2365)</td><td>[415, 5182]</td></tr><tr><td> Prostate</td><td>211</td><td>826</td><td>(555, 1173)</td><td>[98, 3866]</td></tr><tr><td colspan="5"><bold>Gender</bold></td></tr><tr><td> Male</td><td>356</td><td>966</td><td>(636, 1431)</td><td>[98, 4957]</td></tr><tr><td> Female</td><td>360</td><td>839</td><td>(530, 1314)</td><td>[114, 5999]</td></tr><tr><td colspan="5"><bold>Age at registration (years)</bold></td></tr><tr><td> Under 50 years</td><td>129</td><td>778</td><td>(533, 1294)</td><td>[141, 4383]</td></tr><tr><td> 50–59 years</td><td>192</td><td>911</td><td>(572, 1342)</td><td>[114, 5999]</td></tr><tr><td> 60–69 years</td><td>246</td><td>867</td><td>(565, 1315)</td><td>[98, 4957]</td></tr><tr><td> 70 years or older</td><td>149</td><td>1001</td><td>(652, 1509)</td><td>[112, 5182]</td></tr><tr><td colspan="5"><bold>BMI</bold></td></tr><tr><td> BMI &lt; 25</td><td>203</td><td>904</td><td>(590, 1385)</td><td>[103, 4957]</td></tr><tr><td> BMI 25–29.9</td><td>265</td><td>886</td><td>(609, 1337)</td><td>[112, 5182]</td></tr><tr><td> BMI 30–34.9</td><td>124</td><td>813</td><td>(528, 1352)</td><td>[98, 3526]</td></tr><tr><td> BMI &gt; 35</td><td>72</td><td>1011</td><td>(640, 1543)</td><td>[225, 5999]</td></tr><tr><td colspan="5"><bold>Smoking status</bold></td></tr><tr><td> Never</td><td>375</td><td>834</td><td>(526, 1248)</td><td>[103, 5999]</td></tr><tr><td> Ex-smoker</td><td>303</td><td>976</td><td>(602, 1477)</td><td>[98, 5182]</td></tr><tr><td> Current smoker</td><td>38</td><td>1379</td><td>(750, 2182)</td><td>[466, 4957]</td></tr><tr><td colspan="5"><bold>Diabetic</bold></td></tr><tr><td> Not diabetic</td><td>630</td><td>894</td><td>(575, 1361)</td><td>[112, 5182]</td></tr><tr><td> Diabetic</td><td>38</td><td>986</td><td>(745, 1531)</td><td>[98, 5999]</td></tr><tr><td colspan="5"><bold>Receiving BP treatment</bold></td></tr><tr><td> No BP treatment</td><td>492</td><td>909</td><td>(591, 1347)</td><td>[103, 5999]</td></tr><tr><td> On BP treatment</td><td>173</td><td>851</td><td>(569, 1387)</td><td>[98, 4714]</td></tr><tr><td colspan="5"><bold>Statin use in last week</bold></td></tr><tr><td> No statins</td><td>566</td><td>908</td><td>(597, 1366)</td><td>[103, 5182]</td></tr><tr><td> Statin use (within last week)</td><td>111</td><td>859</td><td>(500, 1379)</td><td>[98, 5999]</td></tr><tr><td colspan="5"><bold>Neutrophils (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> Neutrophils &lt;5.0 × 10<sup>9</sup>/L</td><td>601</td><td>879</td><td>(559, 1330)</td><td>[98, 5159]</td></tr><tr><td> Neutrophils ≥5.0 × 10<sup>9</sup>/L</td><td>82</td><td>1134</td><td>(735, 1761)</td><td>[239, 5999]</td></tr><tr><td colspan="5"><bold>Total WCC (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> Total WCC &lt; 8.0 × 10<sup>9</sup>/L</td><td>625</td><td>886</td><td>(566, 1330)</td><td>[98, 5159]</td></tr><tr><td> Total WCC ≥ 8.0 × 10<sup>9</sup>/L</td><td>56</td><td>1212</td><td>(817, 2089)</td><td>[426, 5999]</td></tr><tr><td colspan="5"><bold>Platelet count (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> Platelet count &lt;350 × 10<sup>9</sup>/L</td><td>643</td><td>887</td><td>(569, 1343)</td><td>[98, 5999]</td></tr><tr><td> Platelet count ≥350 × 10<sup>9</sup>/L</td><td>37</td><td>1244</td><td>(834, 1777)</td><td>[185, 4957]</td></tr><tr><td colspan="5"><bold>Raised LDL, total cholesterol or non-HDL</bold></td></tr><tr><td> Normal cholesterol</td><td>270</td><td>920</td><td>(584, 1403)</td><td>[98, 5999]</td></tr><tr><td> Raised LDL, total cholesterol or non-HDL<sup>a</sup></td><td>362</td><td>898</td><td>(568, 1342)</td><td>[114, 5182]</td></tr><tr><td colspan="5"><bold>CRP result (categorised)</bold></td></tr><tr><td> CRP ≤ 5</td><td>562</td><td>875</td><td>(573, 1354)</td><td>[98, 5999]</td></tr><tr><td> CRP &gt; 5</td><td>89</td><td>1079</td><td>(690, 1755)</td><td>[159, 5182]</td></tr><tr><td colspan="5"><bold>Higher-risk disease</bold></td></tr><tr><td> Lower-risk disease</td><td>342</td><td>842</td><td>(531, 1342)</td><td>[114, 4957]</td></tr><tr><td> Higher-risk disease<sup>b</sup></td><td>356</td><td>968</td><td>(650, 1400)</td><td>[98, 5999]</td></tr><tr><td colspan="5"><bold>Primary treatment details</bold></td></tr><tr><td> Surgery, no adjuvant chemo</td><td>250</td><td>828</td><td>(525, 1194)</td><td>[103, 4957]</td></tr><tr><td> Surgery with adjuvant chemo</td><td>350</td><td>1021</td><td>(653, 1558)</td><td>[114, 5999]</td></tr><tr><td> Radical RT or CRT</td><td>100</td><td>824</td><td>(543, 1183)</td><td>[98, 2948]</td></tr><tr><td colspan="5"><bold>Time between surgery and registration</bold></td></tr><tr><td> &lt;12 weeks since surgery</td><td>153</td><td>904</td><td>(597, 1231)</td><td>[103, 4957]</td></tr><tr><td> ≥12 weeks since surgery</td><td>436</td><td>934</td><td>(599, 1484)</td><td>[114, 5999]</td></tr><tr><td colspan="5"><bold>Timing of entry relative to adjuvant chemotherapy</bold></td></tr><tr><td> Surgery without adjuvant chemo</td><td>250</td><td>828</td><td>(525, 1194)</td><td>[103, 4957]</td></tr><tr><td> Surgery and adj chemo—completed</td><td>333</td><td>986</td><td>(613, 1531)</td><td>[114, 5999]</td></tr><tr><td> Surgery and adj chemo—ongoing</td><td>17</td><td>1465</td><td>(1283, 1678)</td><td>[749, 2769]</td></tr><tr><td> All patients</td><td>716</td><td>898</td><td>(572, 1366)</td><td>[98, 5999]</td></tr></tbody></table><table-wrap-foot><p>(B) U-TXM at registration according to baseline factors.</p><p><sup>a</sup>LDL &gt; 3, total cholesterol&gt;5 or non-HDL &gt; 4 defined as elevated; note that participants with at least one of LDL, HDL and total cholesterol measured and in the normal range (and no raised measurements) are included in the normal group even if other measurements are missing.</p><p><sup>b</sup>High-risk disease defined as breast Stage III; colorectal Stage III or IV; gastro-oesophageal Stage IIB or III; prostate high risk according to D’Amico classification.</p><p><sup>c</sup>Participants could not register for the trial until at least 6 weeks post-surgery.</p><p>Neutrophil, platelet and total white cell categories based on upper quartile and above.</p></table-wrap-foot></table-wrap></p>
              <sec id="Sec7">
                <title>Baseline levels of platelet activation after radical treatment for early-stage cancers</title>
                <p id="Par22">Median U-TXM excretion was higher across all the tumour cohorts than observed previously in studies of healthy individuals where the median values were around 500 pg/mg creatinine (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, Table <xref rid="Tab1" ref-type="table">1B</xref> and Supplementary Appendix S<xref rid="MOESM1" ref-type="media">3</xref>) [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Median values (quartile 1, quartile 3) for each cohort were: breast 782 pg/mg (503, 1178), colorectal 1060 pg/mg (667, 1558), gastro-oesophageal 1675 pg/mg (1150, 2365) and prostate 826 pg/mg (555, 1173). The individual data is shown in Supplementary Appendix S<xref rid="MOESM1" ref-type="media">4</xref>. Higher median values (significantly &gt;1000 pg/mg) were associated with the gastro-oesophageal cohort, current smoking, raised neutrophils, total white cells and platelet counts, as well as ongoing adjuvant chemotherapy. Similar levels of U-TXM were seen in participants who were 6–12 weeks from surgery compared to those that were ≥12 weeks, as well in those that had surgery (with no adjuvant chemotherapy) compared to radical radiotherapy or chemoradiotherapy (Table <xref rid="Tab1" ref-type="table">1B</xref> and Appendix S<xref rid="MOESM1" ref-type="media">5</xref>). There was also no significant difference in U-TXM levels between those considered to be at the highest risk of relapse (as defined above) compared to the whole cohort. In multivariable analyses, higher U-TXM excretion was independently associated with tumour type, specifically the colorectal and gastro-oesophageal cohorts compared to the breast cohort (both <italic>P</italic> &lt; 0.001), BMI ≥ 35 kg/m<sup>2</sup> (<italic>P</italic> = 0.008), neutrophils ≥5.0 × 10<sup>9</sup>/l (<italic>P</italic> = 0.003), platelets ≥350 × 10<sup>9</sup>/l (<italic>P</italic> = 0.027) and C-reactive protein (CRP) &gt; 5 mg/L (<italic>P</italic> = 0.046) (Table <xref rid="Tab2" ref-type="table">2A</xref>). The association with tumour type was not accounted for by recent surgery or adjuvant chemotherapy. As a sensitivity analysis, the 17 patients with ongoing chemotherapy at baseline were removed; effect sizes remained similar with tumour type remaining significant.<fig id="Fig2"><label>Fig. 2</label><caption><title>Distribution of U-TXM at registration by tumour-specific cohort—breast (<italic>n</italic> = 260), colorectal (<italic>n</italic> = 192), gastro-oesophageal (<italic>n</italic> = 53), prostate (<italic>n</italic> = 211).</title><p>The dotted line represents the median value in healthy individuals [<xref ref-type="bibr" rid="CR31">31</xref>].</p></caption><graphic xlink:href="41416_2023_2310_Fig2_HTML" id="d32e3506"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Univariable and multivariable models for predicting U-TXM (based on log-transformed values). Panel A at registration and panel B at the end of the run-in period.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="7">(A)</th></tr><tr><th>Baseline characteristic</th><th colspan="3">Univariable models</th><th colspan="3">Multivariable model<sup>d</sup></th></tr><tr><th/><th>Estimate</th><th>(95% CI)</th><th><italic>P</italic> value</th><th>Estimate</th><th>(95% CI)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="7"><bold>Tumour type</bold></td></tr><tr><td> Breast</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Colorectal</td><td>0.28</td><td>(0.16, 0.40)</td><td>&lt;0.001</td><td>0.35</td><td>(0.22, 0.48)</td><td>&lt;0.001</td></tr><tr><td> Gastro-oesophageal</td><td>0.73</td><td>(0.54, 0.92)</td><td>&lt;0.001</td><td>0.71</td><td>(0.51, 0.92)</td><td>&lt;0.001</td></tr><tr><td> Prostate</td><td>−0.01</td><td>(−0.13, 0.11)</td><td>0.856</td><td>0.08</td><td>(−0.12, 0.14)</td><td>0.904</td></tr><tr><td colspan="7"><bold>Gender</bold></td></tr><tr><td> Male</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Female</td><td>−0.11</td><td>(−0.21, −0.02)</td><td>0.023</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Age at registration (years)</bold></td></tr><tr><td> &lt;50 years</td><td>Reference</td><td>−</td><td/><td/><td/><td/></tr><tr><td> 50–59 years</td><td>0.03</td><td>(−0.12, 0.18)</td><td>0.656</td><td/><td/><td/></tr><tr><td> 60–69 years</td><td>0.02</td><td>(−0.13, 0.16)</td><td>0.836</td><td/><td/><td/></tr><tr><td> 70 years or over</td><td>0.15</td><td>(−0.01, 0.31)</td><td>0.063</td><td/><td/><td/></tr><tr><td colspan="7"><bold>BMI</bold></td></tr><tr><td> BMI &lt; 25</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> BMI 25–29.9</td><td>−0.03</td><td>(−0.15, 0.09)</td><td>0.634</td><td/><td/><td/></tr><tr><td> BMI 30–34.9</td><td>−0.11</td><td>(−0.25, 0.04)</td><td>0.154</td><td/><td/><td/></tr><tr><td> BMI 35 or over</td><td>0.14</td><td>(−0.04, 0.32)</td><td>0.116</td><td>0.22</td><td>(0.06, 0.39)</td><td>0.008</td></tr><tr><td colspan="7"><bold>Smoking status</bold></td></tr><tr><td> Never smoked</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Previous smoker</td><td>0.13</td><td>(0.03, 0.23)</td><td>0.011</td><td/><td/><td/></tr><tr><td> Current smoker</td><td>0.46</td><td>(0.24, 0.68)</td><td>&lt;0.001</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Diabetic</bold></td></tr><tr><td> Not diabetic</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Diabetic</td><td>0.09</td><td>(−0.13, 0.31)</td><td>0.414</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Receiving BP treatment</bold></td></tr><tr><td> No BP treatment</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> On BP treatment</td><td>−0.02</td><td>(−0.14, 0.09)</td><td>0.688</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Statin use in last week</bold></td></tr><tr><td> No recent statin use</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Statins within last week</td><td>−0.06</td><td>(−0.19, 0.08)</td><td>0.428</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Neutrophils (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> Neutrophils &lt;5.0 × 10<sup>9</sup>/L</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Neutrophils ≥5.0 × 10<sup>9</sup>/L</td><td>0.31</td><td>(0.15, 0.46)</td><td>&lt;0.001</td><td>0.25</td><td>(0.09, 0.41)</td><td>0.003</td></tr><tr><td colspan="7"><bold>Total WCC (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> Total WCC &lt; 8.0 × 10<sup>9</sup>/L</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Total WCC ≥ 8.0 × 10<sup>9</sup>/L</td><td>0.42</td><td>(0.24, 0.60)</td><td>&lt;0.001</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Platelet count (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> Platelet count &lt;350 × 10<sup>9</sup>/L</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Platelet count ≥350 × 10<sup>9</sup>/L</td><td>0.32</td><td>(0.10, 0.54)</td><td>0.005</td><td>0.26</td><td>(0.03, 0.50)</td><td>0.027</td></tr><tr><td colspan="7"><bold>Raised LDL, total cholesterol or non-HDL</bold></td></tr><tr><td> Normal cholesterol levels</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Raised LDL, total cholesterol or non-HDL<sup>a</sup></td><td>−0.02</td><td>(−0.13, 0.08)</td><td>0.647</td><td/><td/><td/></tr><tr><td colspan="7"><bold>CRP result (categorised)</bold></td></tr><tr><td> CRP ≤ 5</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> CRP &gt; 5</td><td>0.18</td><td>(0.03, 0.33)</td><td>0.017</td><td>0.16</td><td>(0.003, 0.31)</td><td>0.046</td></tr><tr><td colspan="7"><bold>Higher-risk disease</bold></td></tr><tr><td> Lower-risk disease</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Higher-risk disease<sup>b</sup></td><td>0.10</td><td>(0.00, 0.20)</td><td>0.049</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Primary treatment details</bold></td></tr><tr><td> Surgery, no adjuvant chemo</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Surgery and adjuvant chemo</td><td>0.21</td><td>(0.10, 0.32)</td><td>&lt;0.001</td><td/><td/><td/></tr><tr><td> Radical RT or CRT</td><td>−0.05</td><td>(−0.20, 0.11)</td><td>0.538</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Timing of surgery/primary treatment</bold></td></tr><tr><td> 6–12 weeks since surgery<sup>c</sup></td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> &gt;12 weeks since surgery</td><td>0.11</td><td>(−0.01, 0.24)</td><td>0.074</td><td/><td/><td/></tr><tr><td> Radical RT or CRT</td><td>−0.09</td><td>(−0.26, 0.08)</td><td>0.282</td><td/><td/><td/></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="7">(B)</th></tr><tr><th> Baseline characteristic</th><th colspan="3">Univariable models<sup>d</sup></th><th colspan="3">Multivariable model<sup>d</sup></th></tr><tr><th/><th>Estimate</th><th>(95% CI)</th><th><italic>P</italic> value</th><th>Estimate</th><th>(95% CI)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="7"><bold>Tumour type</bold></td></tr><tr><td> Breast</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Colorectal</td><td>0.11</td><td>(−0.02, 0.24)</td><td>0.086</td><td/><td/><td/></tr><tr><td> Gastro-oesophageal</td><td>0.11</td><td>(−0.10, 0.32)</td><td>0.306</td><td/><td/><td/></tr><tr><td> Prostate</td><td>0.00</td><td>(−0.12, 0.12)</td><td>0.975</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Gender</bold></td></tr><tr><td> Male</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Female</td><td>−0.07</td><td>(−0.17, 0.03)</td><td>0.150</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Age at registration (years)</bold></td></tr><tr><td> &lt;50 years</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> 50–59 years</td><td>0.03</td><td>(−0.12, 0.18)</td><td>0.663</td><td/><td/><td/></tr><tr><td> 60–69 years</td><td>−0.01</td><td>(−0.15, 0.13)</td><td>0.915</td><td/><td/><td/></tr><tr><td> 70 years or over</td><td>0.13</td><td>(−0.03, 0.28)</td><td>0.120</td><td>0.13</td><td>(0.003, 0.27)</td><td>0.045</td></tr><tr><td colspan="7"><bold>BMI</bold></td></tr><tr><td> BMI &lt; 25</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> BMI 25–29.9</td><td>−0.09</td><td>(−0.21, 0.03)</td><td>0.162</td><td/><td/><td/></tr><tr><td> BMI 30–34.9</td><td>0.03</td><td>(−0.11, 0.18)</td><td>0.642</td><td/><td/><td/></tr><tr><td> BMI 35 or over</td><td>0.05</td><td>(−0.13, 0.22)</td><td>0.604</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Smoking status</bold></td></tr><tr><td> Never smoked</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Previous smoker</td><td>0.12</td><td>(0.02, 0.22)</td><td>0.024</td><td>0.16</td><td>(0.05, 0.26)</td><td>0.005</td></tr><tr><td> Current smoker</td><td>0.22</td><td>(−0.01, 0.44)</td><td>0.064</td><td>0.31</td><td>(0.04, 0.57)</td><td>0.025</td></tr><tr><td colspan="7"><bold>Diabetic</bold></td></tr><tr><td> Not diabetic</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Diabetic</td><td>0.30</td><td>(0.08, 0.52)</td><td>0.008</td><td>0.31</td><td>(0.06, 0.56)</td><td>0.014</td></tr><tr><td colspan="7"><bold>Receiving BP treatment</bold></td></tr><tr><td> No BP treatment</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> On BP treatment</td><td>0.08</td><td>(−0.03, 0.20)</td><td>0.156</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Statin use in last week</bold></td></tr><tr><td> No recent statin use</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Statins within last week</td><td>0.11</td><td>(−0.03, 0.24)</td><td>0.134</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Neutrophils (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> Neutrophils &lt;5.0 × 10<sup>9</sup>/L</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Neutrophils ≥5.0 × 10<sup>9</sup>/L</td><td>0.21</td><td>(0.05, 0.37)</td><td>0.011</td><td>0.23</td><td>(0.06, 0.40)</td><td>0.008</td></tr><tr><td colspan="7"><bold>Total WCC (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> Total WCC &lt; 8.0 × 10<sup>9</sup>/L</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Total WCC ≥ 8.0 × 10<sup>9</sup>/L</td><td>0.18</td><td>(−0.01, 0.37)</td><td>0.067</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Platelet count (10</bold><sup><bold>9</bold></sup><bold>/L)</bold></td></tr><tr><td> Platelet count &lt;350 × 10<sup>9</sup>/L</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Platelet count ≥350 × 10<sup>9</sup>/L</td><td>−0.04</td><td>(−0.27, 0.19)</td><td>0.748</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Raised LDL, total cholesterol or non-HDL</bold></td></tr><tr><td> Normal cholesterol levels</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Raised LDL, total cholesterol or non-HDL<sup>a</sup></td><td>−0.04</td><td>(−0.14, 0.07)</td><td>0.457</td><td/><td/><td/></tr><tr><td colspan="7"><bold>CRP result (categorised)</bold></td></tr><tr><td> CRP ≤ 5</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> CRP &gt; 5</td><td>0.22</td><td>(0.06, 0.37)</td><td>0.006</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Higher-risk disease</bold></td></tr><tr><td> Lower-risk disease</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Higher-risk disease<sup>b</sup></td><td>−0.09</td><td>(−0.19, 0.01)</td><td>0.083</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Primary treatment details</bold></td></tr><tr><td> Surgery, no adjuvant chemo</td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> Surgery and adjuvant chemo</td><td>0.02</td><td>(−0.09, 0.13)</td><td>0.664</td><td/><td/><td/></tr><tr><td> Radical RT or CRT</td><td>0.04</td><td>(−0.11, 0.20)</td><td>0.577</td><td/><td/><td/></tr><tr><td colspan="7"><bold>Timing of surgery/primary treatment</bold></td></tr><tr><td> 6–12 weeks since surgery<sup>c</sup></td><td>Reference</td><td>–</td><td/><td/><td/><td/></tr><tr><td> &gt;12 weeks since surgery</td><td>0.06</td><td>(−0.07, 0.18)</td><td>0.380</td><td/><td/><td/></tr><tr><td> Radical RT or CRT</td><td>0.07</td><td>(−0.10, 0.24)</td><td>0.418</td><td/><td/><td/></tr></tbody></table><table-wrap-foot><p>Univariable and multivariable models for predicting U-TXM (based on log-transformed values of U-TXM) at baseline (trial registration) (Panel A) and at the end run-in period (Panel B). </p><p><sup>a</sup>LDL &gt; 3, total cholesterol &gt;5 or non-HDL &gt; 4; note that participants with at least one of LDL, HDL and total cholesterol measured and in the normal range (and no raised measurements) are included in the normal group even if other measurements are missing.</p><p><sup>b</sup>Breast Stage III; colorectal Stage III or IV; gastro-oesophageal Stage IIB or III; prostate high risk according to D’Amico classification.</p><p><sup>c</sup>Timing of surgery was not considered in the multivariate model due to being confounded with the primary treatment variable and since it was non-significant in the univariate model.</p><p><sup>d</sup>The final multivariable model at registration is based on <italic>n</italic> = 552 observations (some observations are not included due to missing covariate information—see earlier table); <italic>R</italic><sup>2</sup> = 16.8%. At the end of the run-in period the final multivariable model is based on <italic>n</italic> = 402 observations <italic>R</italic><sup>2</sup> = 32.3%. All models are adjusted for (log-transformed) baseline U-TXM.</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec8">
                <title>The effect of low-dose aspirin (100 mg daily) on in vivo platelet activation</title>
                <p id="Par23">At the end of the run-in period, urine samples from 522 participants were available (breast 193, colorectal 134, gastro-oesophageal 35, prostate 160) with 8 participants excluded due to reported poor adherence. Characteristics of participants who provided samples at the end of run-in were similar to the overall study cohort except that there were slightly fewer ex/current smokers (data not shown). Aspirin 100 mg daily suppressed U-TXM excretion similarly across all four cohorts (Fig. <xref rid="Fig3" ref-type="fig">3a, b</xref>) with a median percentage reduction of 76% consistent with previous data in other clinical settings [<xref ref-type="bibr" rid="CR31">31</xref>]. Univariable and multivariable models were used to examine U-TXM at the end of the run-in period (Table <xref rid="Tab2" ref-type="table">2B</xref>) with age ≥70 years (<italic>P</italic> = 0.045), current/previous smoking (<italic>P</italic> = 0.005 and <italic>P</italic> = 0.025, respectively), diabetes (<italic>P</italic> = 0.014) and neutrophils ≥5.0 × 10<sup>9</sup>/l (<italic>P</italic> = 0.008) being independently associated with higher levels in the multivariable analysis after adjustment for baseline U-TXM. For 14/522 (2.7%) of participants, U-TXM was the same or higher than baseline (6 breast, 4 colorectal and 4 prostate) at the end of run-in period. There was higher proportion of diabetics and current/previous smokers in this group compared to the whole cohort and it is also possible that adherence was not as reported.<fig id="Fig3"><label>Fig. 3</label><caption><title>U-TXM levels at the end of the run-in period after 8 weeks of aspirin 100 mg daily.</title><p>Panel <bold>a</bold> by tumour cohort and Panel <bold>b</bold> for the whole group.</p></caption><graphic xlink:href="41416_2023_2310_Fig3_HTML" id="d32e5268"/></fig></p>
              </sec>
              <sec id="Sec9">
                <title>The effect of aspirin dose on in vivo platelet activation</title>
                <p id="Par24">Urine samples from 327 participants were available after at least 3 months post-random allocation (1:1:1) to 100 mg aspirin, 300 mg aspirin or matched placebo. Median U-TXM was similar in the two aspirin groups (194 and 159 pg/mg for 100 mg and 300 mg, respectively) and much lower than in the placebo group, where it was close to pre-treatment levels (median 752 pg/ml) (Supplementary Appendix S<xref rid="MOESM1" ref-type="media">6</xref>). Absolute and percentage changes in U-TXM compared to the end of run-in sample were minimal on aspirin 100 and 300 mg daily while in the placebo arm there was an approximately threefold increase (median absolute increase of 530 pg/mg) as expected. A summary of changes in U-TXM over time for each of the three groups (placebo, aspirin 100 mg and aspirin 300 mg) is shown in Fig. <xref rid="Fig4" ref-type="fig">4</xref>. It illustrates similar levels of suppression of platelet activation for the two aspirin doses and a return to near baseline levels when participants received placebo and provides reassurance that the majority of participants are complying with the treatment schedule and not consuming additional over-the-counter aspirin. Absolute and percentage change between the baseline and the 3-month follow-up timepoint are shown in Supplementary Appendix S<xref rid="MOESM1" ref-type="media">7</xref>. An analysis of the effects of aspirin dose (100 mg versus 300 mg daily) considered by baseline factors known to affect platelet activation (Supplementary Appendix S<xref rid="MOESM1" ref-type="media">8</xref>) shows slightly lower median values for the 300 mg aspirin group, though no definitive evidence that a higher dose would be more effective in some subgroups (noting that numbers in some of the categories are small).<fig id="Fig4"><label>Fig. 4</label><caption><title>U-TXM levels over time at 3 time points (baseline, end of run-in and 3–6 months after random allocation).</title><p>Panel <bold>a</bold>–<bold>c</bold> random allocation to aspirin 100 mg, 300 mg and matched placebo respectively.</p></caption><graphic xlink:href="41416_2023_2310_Fig4_HTML" id="d32e5302"/></fig></p>
              </sec>
            </sec>
            <sec id="Sec10" sec-type="discussion">
              <title>Discussion</title>
              <p id="Par25">To our knowledge, this is the largest and most detailed study of thromboxane biosynthesis in patients with early-stage cancer. Increased levels of U-TXM excretion were found in all the tumour cohorts compared to previous studies of healthy individuals measured in the same laboratory [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. The levels were higher than expected given all of the patients had been treated with radical intent and had no clinical evidence of metastatic disease when they entered the trial. Expected 5-year disease-free survival rates vary by tumour type but range from around 55% for the gastro-oesophageal participants to over 80% for those with breast and prostate cancer. With the exception of 17 (2%) of the participants, cancer treatment (chemotherapy or radiotherapy) had finished several weeks (no more than 6–14 weeks) before entry into the study, and all patients were at least 6 weeks from surgery with over 50% more than 12 weeks. The data also show that for the patients allocated to placebo after the run-in period U-TXM levels return to near baseline levels suggesting persistently enhanced thromboxane biosynthesis. The highest levels were associated with tumours that arose from the gastrointestinal tract (i.e., the colorectal and gastro-oesophageal cohorts) compared to the breast and prostate cohorts. In the multivariable analysis, this was not accounted for by baseline participant characteristics or treatment factors such as time from recent radical therapy (surgery or radiotherapy) or receiving adjuvant chemotherapy.</p>
              <p id="Par26">Consistent with previous literature, high U-TXM levels at baseline were also associated with known inflammatory stimuli, or markers thereof, including high BMI, a history of smoking, raised total white cells, neutrophils, and higher platelet counts [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>–<xref ref-type="bibr" rid="CR46">46</xref>]. In the multivariable analysis, raised inflammatory markers, higher platelet numbers and BMI &gt;35 remained statistically significant. The variation of thromboxane biosynthesis across the tumour cohorts is an interesting observation given studies suggest that aspirin may be most effective in preventing cancers that arise from the gastrointestinal tract [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p>
              <p id="Par27">The biological plausibility of, and supporting evidence, for the role of platelet activation in colorectal cancer has been reviewed previously [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. The differential increase of U-TXM observed in colorectal and gastro-oesophageal cancers vis-à-vis breast and prostate is consistent with the hypothesised role of platelets in intestinal tumorigenesis [<xref ref-type="bibr" rid="CR1">1</xref>]. The role of platelets in breast and prostate cancer has been less intensively investigated, but a recent breast cancer study that correlated U-TXM, urinary markers of oxidative stress and clinical characteristics suggested enhanced oxidative stress due to insulin resistance and oestrogen-related mechanisms may cause platelet activation and a positive environment for tumour growth [<xref ref-type="bibr" rid="CR49">49</xref>]. Similarly in a prostate cancer case–control study higher levels of U-TXM were associated with higher-risk disease and poorer outcomes [<xref ref-type="bibr" rid="CR50">50</xref>]. Studies also show increased levels of TXA<sub>2</sub> synthase and TXA<sub>2</sub> receptors in multiple tumour types (though rarely mutated) leading to the hypothesis that thromboxane receptor antagonists which would also decrease TXA<sub>2</sub> production in tumours should also be assessed for their anti-metastatic potential [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
              <p id="Par28">Aspirin’s main mechanism of action at low dose (75–100 mg daily) is the acetylation of platelet COX-1 at serine-529 [<xref ref-type="bibr" rid="CR9">9</xref>] resulting in 70–80% suppression of U-TXM, with recovery of excretion corresponding to the platelet lifespan (7–10 days) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Under pathophysiological conditions COX-2 in renal and inflammatory cells may contribute to enhanced TXA<sub>2</sub> production [<xref ref-type="bibr" rid="CR52">52</xref>], however, both are largely unaffected by low aspirin doses [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Although urinary prostanoid metabolites do not reflect a specific cellular source, there is considerable evidence that urinary TXA<sub>2</sub>/TXB<sub>2</sub> metabolites largely originate from platelet-derived TXA<sub>2</sub> as reviewed previously [<xref ref-type="bibr" rid="CR31">31</xref>]. Recent data to support this hypothesis derives from the pPtgs1<sup>−/−</sup> mice with the deletion of COX-1 in megakaryocytes and platelets. These mice have a selective reduction of platelet TXA<sub>2</sub> biosynthesis, as reflected by a 70% reduction in U-TXM excretion, but the systemic biosynthesis of PGE<sub>2</sub>, PGI<sub>2</sub> and PGD<sub>2</sub>, as assessed by measuring their major urinary enzymatic metabolites, i.e., PGEM, PGIM and PGDM, respectively, is not significantly affected [<xref ref-type="bibr" rid="CR14">14</xref>]. Our finding that the extent of U-TXM suppression (averaging 76%) by aspirin 100 mg was not further increased by a threefold higher daily dose is consistent with the saturability of platelet COX-1 inactivation at the lower dose. Although low-dose aspirin (100 mg daily) can acetylate COX-1 in the colorectal mucosa [<xref ref-type="bibr" rid="CR53">53</xref>], the level of acetylation is lower than in circulating platelets and is associated with marginal (i.e., &lt;10%) reduction in urinary PGEM.</p>
              <p id="Par29">The present findings in cancer patients are consistent with the saturability of platelet COX-1 inactivation at low aspirin doses with a three-quarter reduction in TXA<sub>2</sub> biosynthesis with 100 mg aspirin daily and no further meaningful reduction observed with 300 mg daily [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. In addition, our findings are similar to those in healthy volunteers where aspirin 100 mg daily reduced U-TXM excretion by 65–70% following 1- to 8-week dosing [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>], suggesting a similar primary source of increased TXA<sub>2</sub> biosynthesis.</p>
              <p id="Par30">Increasing age, cigarette smoking and obesity all lead to chronic, low-grade inflammation, and are independently well-defined aetiological factors associated with malignancy, attributed in part to their effects on platelet activation [<xref ref-type="bibr" rid="CR57">57</xref>]. Our data could potentially help to identify individuals most likely to benefit from aspirin for the primary prevention of cancer, i.e., those with high levels of thromboxane production associated with known risk factors for cancer. Our observation that higher platelet counts were associated with increased levels of thromboxane biosynthesis aligns with recent data suggesting that platelet counts (or possibly platelet characteristics) could be used as an early indicator/screening tool to detect cancer [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. The 1-year incidence of cancer in patients with thrombocytosis (&gt;400 × 10<sup>9</sup>/L) has been shown to exceed the UK national threshold for investigating possible cancer cases with data also suggesting that in older males (≥60 years) a platelet count in the high-normal range (&gt;325 × 10<sup>9</sup>/L) is also associated with an increased cancer risk [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. The utility of platelet counts and markers of activation to monitor cancer progression is more challenging as many cancer-related treatments effect platelets [<xref ref-type="bibr" rid="CR61">61</xref>].</p>
              <p id="Par31">The mechanism(s) by which aspirin exerts an anti-cancer effect remains speculative, but our data suggest a plausible link between the known pharmacological effects of aspirin and previous clinical observations by demonstrating persistently enhanced thromboxane A<sub>2</sub> generation in patients recently diagnosed with cancer. The data also support the ongoing evaluation of two aspirin dose levels within the Add-Aspirin trial for two reasons. Firstly, our results demonstrate an adequate pharmacodynamic response to low-dose aspirin in cancer patients, comparable to that achieved in other clinical settings, such as cardiovascular disease where clinical efficacy has been demonstrated. Secondly, the lack of a further reduction in TXA<sub>2</sub> biosynthesis in response to the higher aspirin dose, means that any dose-related pattern in efficacy and/or safety can be interpreted as reflecting an extra-platelet target of aspirin. Several mechanisms independent of inhibition of platelet activation have been hypothesised to explain the anti-cancer effects of aspirin [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>] and targeting these pathways may then require a higher dose of aspirin.</p>
              <p id="Par32">Since this study was embedded within a randomised-controlled trial which incorporates a placebo arm, it provides a robust and valuable dataset for investigating the effects of aspirin on thromboxane biosynthesis. Nevertheless, there are some limitations. U-TXM is one major enzymatic metabolite of TXA<sub>2</sub>/TXB<sub>2</sub> that can also be metabolised to 2,3-dinor-TXB<sub>2</sub>. Our study did not include measurements of 2,3-dinor-TXB<sub>2</sub>, but our previous work in diabetic patients with enhanced excretion of U-TXM found a linear conversion of exogenously infused TXB<sub>2</sub> to U-TXM over a 50-fold range of infusion rates (with a fractional elimination similar to healthy subjects) suggesting increased biosynthesis of TXA<sub>2</sub>/TXB<sub>2</sub> rather than a shift in its metabolic disposition [<xref ref-type="bibr" rid="CR46">46</xref>]. The current finding of raised U-TXM associated with high BMI and inflammatory markers in cancer patients is similar to other non-cancer clinical settings, e.g., obesity and type II diabetes mellitus studied previously [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>] and leads us to believe that the fractional conversion of endogenous TXA<sub>2</sub>/TXB<sub>2</sub> to U-TXM would be similarly unaltered in cancer patients.</p>
              <p id="Par33">Other limitations of this study are in part related to the design of the main trial including the range of aspirin doses that could be evaluated. Additionally, measurement of serum TXB<sub>2</sub> or markers of platelet aggregation would have required on-site pre-analytical processing [<xref ref-type="bibr" rid="CR64">64</xref>] and was not logistically possible in this large pragmatic trial. However, given that U-TXM excretion was suppressed by aspirin 100 mg daily to the same extent as previously reported in healthy subjects, it is reasonable to assume that platelet COX-1 activity was comparably suppressed. By necessity, the analyses of samples from beyond the baseline timepoint could only include participants who continued with trial treatment. This might impact the generalisability of the results, but the numbers stopping treatment or participation were small and we did not identify any important differences between these participants compared to the whole trial cohort. Finally, the lack of longer-term clinical outcomes, i.e., recurrence and survival data, for correlation with U-TXM levels at the present time is not possible as the randomised trial is still ongoing.</p>
              <p id="Par34">In summary, this study found that patients who have had a recent diagnosis of cancer and radical therapy showed evidence of persistently increased thromboxane biosynthesis as measured by U-TXM excretion compared to healthy individuals. This was most marked in the colorectal and gastro-oesophageal participants independent of pro-inflammatory baseline characteristics and recent anti-cancer treatment. Our findings show comparable suppression of U-TXM with aspirin 100 and 300 mg daily and are consistent with the saturability of platelet COX-1 inactivation at low doses. Within this cohort of participants adherence with randomly allocated blinded treatment appeared good. These findings may help interpret the clinical results of the Add-Aspirin trial and other aspirin oncology trials subsequently. This is particularly important given the differences we have observed between the tumour types in this study; as with other anti-cancer drugs the effects of aspirin may vary with different cancer types, molecular pathways driving the disease and the specific tumour microenvironment. Further studies are required to assess whether regular monitoring of U-TXM levels might provide an early indicator of tumour development or recurrence and a novel biomarker particularly in gastrointestinal cancers.</p>
            </sec>
            <sec id="Sec11">
              <title>Disclaimer</title>
              <p id="Par35">The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary information</title>
              <sec id="Sec12">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="41416_2023_2310_MOESM1_ESM.docx">
                      <caption>
                        <p>Supplementary Appendix</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
              <fn>
                <p>These authors contributed equally: Nalinie Joharatnam-Hogan, Duaa Hatem.</p>
              </fn>
              <fn>
                <p>These authors jointly supervised this work: Bianca Rocca, Ruth E. Langley.</p>
              </fn>
            </fn-group>
            <sec>
              <title>Supplementary information</title>
              <p>The online version contains supplementary material available at 10.1038/s41416-023-02310-1.</p>
            </sec>
            <ack>
              <title>Acknowledgements</title>
              <p>We thank the study participants and their families and carers, site research staff, members of the wider Add-Aspirin trial management groups, trial steering committee, independent data monitoring committee and the Aspirin for Cancer Prevention (AsCaP) steering committee members.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>RL is the lead Investigator. NJ-H, DH, FC, CP, BR and RL were responsible for the conceptualisation and design of the study. DC, AR, DG, RW, RH, DS, MS-B, SS, LD, LC, MC, DC, VK, AA, NA, GH, DW, RM, FL, AW, RH, JE, AO, AE, MK, DP, KN, JB, ZS, AR, GW, VK and NS contributed to participant recruitment and sample collection. AR contributed to the collation of data and sample transfer. DH, GP, CP and BR were responsible for experimental analysis and interpretation. RL, DC, AR, HK, DG, RW, RH, DS, AG-M and AM were responsible for oversight of the conduct of the trial. FC was responsible for statistical analysis. NJ-H, DH, CP, BR and RL were responsible for drafting the manuscript. All other authors reviewed and approved the final manuscript.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>This work was specifically supported by CRUK (C471/A19252) and the AsCaP collaboration (C569/A24991). The main trial is supported by grants from Cancer Research UK (C471/A15015), the National Institute for Health Research Health Technology Assessment Programme (12/01/38) and the MRC (MC_UU_00004/02 and MC_UU_12023/28). Bayer Pharmaceuticals AG provided aspirin and placebo, free of charge. <italic>The role of the funder:</italic> The sponsor had no role in the design, analysis or decision to publish.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>The trial data are held at MRC CTU at UCL, which encourages optimal use of data by use of a controlled access approach to data sharing. Requests for data can be made at any time and can be initiated by contacting mrcctu.ctuenquiries@ucl.ac.uk or via the MRC CTU website. There is a formal application process, whereby the request will undergo review by the trial team, as well as independent researchers, to ensure that the proposed research is both ethical and has a strong scientific rationale. Data will not be released if it would compromise the ongoing trial. The specific data and associated documents to be shared will be dependent on the nature of the individual request and this will be documented in a formal data-sharing agreement.</p>
            </notes>
            <notes id="FPar1" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par36">DC reports grants from MedImmune/ AstraZeneca, Clovis, Eli Lilly, 4SC, Bayer, Celgene, NIHR EME, Leap, Roche and ownership interest and advisory role to OVIBIO. VK reports honoraria for speakers’ bureaus, personal fees and non-financial support from Accuray, Astellas, Bayer, Boston Scientific, and Janssen. DW reports sponsorship from Roche, AstraZeneca, Novartis, Pfizer for ad boards and travel fees from Roche. AW reports consulting fees from GlaxoSmithKline, Clovis, MSD and conference attendance from GlaxoSmithKline. VK reports honorarium from Servier, Roche, Amgen and Clovis Oncology pharmaceutical companies for presentation, educational meeting support, and article write-up. AG-M is a co-investigator on studies exploring novel biomarkers in ovarian cancer, funded by Micronoma and iLoF, with the research funding awarded to UCL. CP reports personal fees from Acticor Biotech, Amgen, Bayer, Eli Lilly, Tremeau, and Zambon; institutional grants from AIFA (Italian Medicines Agency), Bayer, Cancer Research UK, and European Commission; he chairs the Scientific Advisory Board of the International Aspirin Foundation. BR reports speaker fees from Swedish Orphan Biovitrum AB, a grant for an investigator-initiated trial from Bayer AG and consulting fees from Aboca. RL reports grant funding for the Add-Aspirin trial and the AsCaP collaboration, and honorarium from the Aspirin Foundation supported by Bayer. The remaining authors declare no competing interests.</p>
            </notes>
            <notes id="FPar2">
              <title>Ethics approval and consent to participate</title>
              <p id="Par37">The trial protocol, including the platelet activation sub-study, was approved by South Central-Oxford C research ethics committee (Ref: 14/SC/0171) and by local research and development departments at all centres. Participants provided written informed consent. The study was performed in accordance with the Declaration of Helsinki.</p>
            </notes>
            <notes id="FPar3">
              <title>Consent for publication</title>
              <p id="Par38">Not applicable.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patrignani</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Patrono</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Aspirin, platelet inhibition and cancer prevention</article-title>
                  <source>Platelets.</source>
                  <year>2018</year>
                  <volume>29</volume>
                  <fpage>779</fpage>
                  <lpage>85</lpage>
                  <pub-id pub-id-type="doi">10.1080/09537104.2018.1492105</pub-id>
                  <?supplied-pmid 29985750?>
                  <pub-id pub-id-type="pmid">29985750</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Palacios-Acedo</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Mege</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Crescence</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Dignat-George</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Dubois</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Panicot-Dubois</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>Platelets, thrombo-inflammation, and cancer: collaborating with the enemy</article-title>
                  <source>Front Immunol</source>
                  <year>2019</year>
                  <volume>10</volume>
                  <fpage>1805</fpage>
                  <pub-id pub-id-type="doi">10.3389/fimmu.2019.01805</pub-id>
                  <?supplied-pmid 31417569?>
                  <pub-id pub-id-type="pmid">31417569</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Franco</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Corken</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ware</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Platelets at the interface of thrombosis, inflammation, and cancer</article-title>
                  <source>Blood.</source>
                  <year>2015</year>
                  <volume>126</volume>
                  <fpage>582</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1182/blood-2014-08-531582</pub-id>
                  <?supplied-pmid 26109205?>
                  <pub-id pub-id-type="pmid">26109205</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Metharom</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Falasca</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Berndt</surname>
                      <given-names>MC</given-names>
                    </name>
                  </person-group>
                  <article-title>The history of Armand Trousseau and cancer-associated thrombosis</article-title>
                  <source>Cancers (Basel)</source>
                  <year>2019</year>
                  <volume>11</volume>
                  <fpage>158</fpage>
                  <pub-id pub-id-type="doi">10.3390/cancers11020158</pub-id>
                  <?supplied-pmid 30708967?>
                  <pub-id pub-id-type="pmid">30708967</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lucotti</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Muschel</surname>
                      <given-names>RJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Platelets and metastasis: new implications of an old interplay</article-title>
                  <source>Front Oncol</source>
                  <year>2020</year>
                  <volume>10</volume>
                  <fpage>1350</fpage>
                  <pub-id pub-id-type="doi">10.3389/fonc.2020.01350</pub-id>
                  <?supplied-pmid 33042789?>
                  <pub-id pub-id-type="pmid">33042789</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schlesinger</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Role of platelets and platelet receptors in cancer metastasis</article-title>
                  <source>J Hematol Oncol</source>
                  <year>2018</year>
                  <volume>11</volume>
                  <fpage>125</fpage>
                  <pub-id pub-id-type="doi">10.1186/s13045-018-0669-2</pub-id>
                  <?supplied-pmid 30305116?>
                  <pub-id pub-id-type="pmid">30305116</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meikle</surname>
                      <given-names>CK</given-names>
                    </name>
                    <name>
                      <surname>Kelly</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Garg</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Wuescher</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Ali</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Worth</surname>
                      <given-names>RG</given-names>
                    </name>
                  </person-group>
                  <article-title>Cancer and thrombosis: the platelet perspective</article-title>
                  <source>Front Cell Dev Biol</source>
                  <year>2016</year>
                  <volume>4</volume>
                  <fpage>147</fpage>
                  <?supplied-pmid 28105409?>
                  <pub-id pub-id-type="pmid">28105409</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patrono</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Aspirin as an antiplatelet drug</article-title>
                  <source>N Engl J Med</source>
                  <year>1994</year>
                  <volume>330</volume>
                  <fpage>1287</fpage>
                  <lpage>94</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJM199405053301808</pub-id>
                  <?supplied-pmid 8145785?>
                  <pub-id pub-id-type="pmid">8145785</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patrignani</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Tacconelli</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Piazuelo</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Di Francesco</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Dovizio</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sostres</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action</article-title>
                  <source>J Thromb Haemost</source>
                  <year>2014</year>
                  <volume>12</volume>
                  <fpage>1320</fpage>
                  <lpage>30</lpage>
                  <pub-id pub-id-type="doi">10.1111/jth.12637</pub-id>
                  <?supplied-pmid 24942808?>
                  <pub-id pub-id-type="pmid">24942808</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Thun</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Jacobs</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Patrono</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of aspirin in cancer prevention</article-title>
                  <source>Nat Rev Clin Oncol</source>
                  <year>2012</year>
                  <volume>9</volume>
                  <fpage>259</fpage>
                  <lpage>67</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrclinonc.2011.199</pub-id>
                  <?supplied-pmid 22473097?>
                  <pub-id pub-id-type="pmid">22473097</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Guillem-Llobat</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Dovizio</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bruno</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ricciotti</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Cufino</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Sacco</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells</article-title>
                  <source>Oncotarget.</source>
                  <year>2016</year>
                  <volume>7</volume>
                  <fpage>32462</fpage>
                  <lpage>77</lpage>
                  <pub-id pub-id-type="doi">10.18632/oncotarget.8655</pub-id>
                  <?supplied-pmid 27074574?>
                  <pub-id pub-id-type="pmid">27074574</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lucotti</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Cerutti</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Soyer</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gil-Bernabe</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Gomes</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Allen</surname>
                      <given-names>PD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2</article-title>
                  <source>J Clin Invest</source>
                  <year>2019</year>
                  <volume>129</volume>
                  <fpage>1845</fpage>
                  <lpage>62</lpage>
                  <pub-id pub-id-type="doi">10.1172/JCI121985</pub-id>
                  <?supplied-pmid 30907747?>
                  <pub-id pub-id-type="pmid">30907747</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Dubois</surname>
                      <given-names>RN</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of COX-2 in intestinal inflammation and colorectal cancer</article-title>
                  <source>Oncogene.</source>
                  <year>2010</year>
                  <volume>29</volume>
                  <fpage>781</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1038/onc.2009.421</pub-id>
                  <?supplied-pmid 19946329?>
                  <pub-id pub-id-type="pmid">19946329</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bruno</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Contursi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Tacconelli</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Sacco</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hofling</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Mucci</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The specific deletion of cyclooxygenase-1 in megakaryocytes/platelets reduces intestinal polyposis in Apc(Min/+) mice</article-title>
                  <source>Pharm Res</source>
                  <year>2022</year>
                  <volume>185</volume>
                  <fpage>106506</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.phrs.2022.106506</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ashton</surname>
                      <given-names>AW</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Cazzolli</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Honn</surname>
                      <given-names>KV</given-names>
                    </name>
                  </person-group>
                  <article-title>The role and regulation of thromboxane A(2) signaling in cancer-trojan horses and misdirection</article-title>
                  <source>Molecules.</source>
                  <year>2022</year>
                  <volume>27</volume>
                  <fpage>6234</fpage>
                  <pub-id pub-id-type="doi">10.3390/molecules27196234</pub-id>
                  <?supplied-pmid 36234768?>
                  <pub-id pub-id-type="pmid">36234768</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pulley</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Jerome</surname>
                      <given-names>RN</given-names>
                    </name>
                    <name>
                      <surname>Ogletree</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Bernard</surname>
                      <given-names>GR</given-names>
                    </name>
                    <name>
                      <surname>Lavieri</surname>
                      <given-names>RR</given-names>
                    </name>
                    <name>
                      <surname>Zaleski</surname>
                      <given-names>NM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Motivation for launching a cancer metastasis inhibition (CMI) program</article-title>
                  <source>Target Oncol</source>
                  <year>2018</year>
                  <volume>13</volume>
                  <fpage>61</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11523-017-0542-1</pub-id>
                  <?supplied-pmid 29218624?>
                  <pub-id pub-id-type="pmid">29218624</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Frouws</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Bastiaannet</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Langley</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Chia</surname>
                      <given-names>WK</given-names>
                    </name>
                    <name>
                      <surname>van Herk-Sukel</surname>
                      <given-names>MP</given-names>
                    </name>
                    <name>
                      <surname>Lemmens</surname>
                      <given-names>VE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study</article-title>
                  <source>Br J Cancer</source>
                  <year>2017</year>
                  <volume>116</volume>
                  <fpage>405</fpage>
                  <lpage>13</lpage>
                  <pub-id pub-id-type="doi">10.1038/bjc.2016.425</pub-id>
                  <?supplied-pmid 28072768?>
                  <pub-id pub-id-type="pmid">28072768</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bosetti</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Santucci</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Gallus</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Martinetti</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>La Vecchia</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019</article-title>
                  <source>Ann Oncol</source>
                  <year>2020</year>
                  <volume>31</volume>
                  <fpage>558</fpage>
                  <lpage>68</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.annonc.2020.02.012</pub-id>
                  <?supplied-pmid 32272209?>
                  <pub-id pub-id-type="pmid">32272209</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Simon</surname>
                      <given-names>TG</given-names>
                    </name>
                    <name>
                      <surname>Duberg</surname>
                      <given-names>AS</given-names>
                    </name>
                    <name>
                      <surname>Aleman</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Chung</surname>
                      <given-names>RT</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Ludvigsson</surname>
                      <given-names>JF</given-names>
                    </name>
                  </person-group>
                  <article-title>Association of aspirin with hepatocellular carcinoma and liver-related mortality</article-title>
                  <source>N Engl J Med</source>
                  <year>2020</year>
                  <volume>382</volume>
                  <fpage>1018</fpage>
                  <lpage>28</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1912035</pub-id>
                  <?supplied-pmid 32160663?>
                  <pub-id pub-id-type="pmid">32160663</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rothwell</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Fowkes</surname>
                      <given-names>FG</given-names>
                    </name>
                    <name>
                      <surname>Belch</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Ogawa</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Warlow</surname>
                      <given-names>CP</given-names>
                    </name>
                    <name>
                      <surname>Meade</surname>
                      <given-names>TW</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials</article-title>
                  <source>Lancet.</source>
                  <year>2011</year>
                  <volume>377</volume>
                  <fpage>31</fpage>
                  <lpage>41</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(10)62110-1</pub-id>
                  <?supplied-pmid 21144578?>
                  <pub-id pub-id-type="pmid">21144578</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <mixed-citation publication-type="other">NICE guideline [NG151]. Colorectal Cancer. 29 January 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ng151">https://www.nice.org.uk/guidance/ng151</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Burn</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sheth</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Elliott</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Reed</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Macrae</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Mecklin</surname>
                      <given-names>JP</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial</article-title>
                  <source>Lancet.</source>
                  <year>2020</year>
                  <volume>395</volume>
                  <fpage>1855</fpage>
                  <lpage>63</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30366-4</pub-id>
                  <?supplied-pmid 32534647?>
                  <pub-id pub-id-type="pmid">32534647</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cuzick</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Thorat</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Bosetti</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>PH</given-names>
                    </name>
                    <name>
                      <surname>Burn</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Cook</surname>
                      <given-names>NR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Estimates of benefits and harms of prophylactic use of aspirin in the general population</article-title>
                  <source>Ann Oncol</source>
                  <year>2015</year>
                  <volume>26</volume>
                  <fpage>47</fpage>
                  <lpage>57</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdu225</pub-id>
                  <?supplied-pmid 25096604?>
                  <pub-id pub-id-type="pmid">25096604</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chan</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Aspirin and the USPSTF—what about cancer?</article-title>
                  <source>JAMA Oncol</source>
                  <year>2022</year>
                  <volume>8</volume>
                  <fpage>1392</fpage>
                  <lpage>4</lpage>
                  <pub-id pub-id-type="doi">10.1001/jamaoncol.2022.2967</pub-id>
                  <?supplied-pmid 35900749?>
                  <pub-id pub-id-type="pmid">35900749</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <mixed-citation publication-type="other">Patrono C. Cyclooxygenase inhibitors and cancer: The missing pieces. J Pharmacol Exp Ther. 2023 [Epub ahead of print].</mixed-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ay</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Pabinger</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>AT</given-names>
                    </name>
                  </person-group>
                  <article-title>Cancer-associated venous thromboembolism: burden, mechanisms, and management</article-title>
                  <source>Thromb Haemost</source>
                  <year>2017</year>
                  <volume>117</volume>
                  <fpage>219</fpage>
                  <lpage>30</lpage>
                  <pub-id pub-id-type="doi">10.1160/TH16-08-0615</pub-id>
                  <?supplied-pmid 27882374?>
                  <pub-id pub-id-type="pmid">27882374</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moik</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Ay</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer</article-title>
                  <source>J Thromb Haemost</source>
                  <year>2022</year>
                  <volume>20</volume>
                  <fpage>2733</fpage>
                  <lpage>45</lpage>
                  <pub-id pub-id-type="doi">10.1111/jth.15880</pub-id>
                  <?supplied-pmid 36106749?>
                  <pub-id pub-id-type="pmid">36106749</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yeini</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Satchi-Fainaro</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of P-selectin in cancer-associated thrombosis and beyond</article-title>
                  <source>Thromb Res</source>
                  <year>2022</year>
                  <volume>213</volume>
                  <fpage>S22</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.thromres.2021.12.027</pub-id>
                  <?supplied-pmid 36210556?>
                  <pub-id pub-id-type="pmid">36210556</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Riedl</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hell</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Kaider</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Koder</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Marosi</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Zielinski</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Association of platelet activation markers with cancer-associated venous thromboembolism</article-title>
                  <source>Platelets.</source>
                  <year>2016</year>
                  <volume>27</volume>
                  <fpage>80</fpage>
                  <lpage>5</lpage>
                  <pub-id pub-id-type="doi">10.3109/09537104.2015.1041901</pub-id>
                  <?supplied-pmid 25970326?>
                  <pub-id pub-id-type="pmid">25970326</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hamberg</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Svensson</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Samuelsson</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides</article-title>
                  <source>Proc Natl Acad Sci USA</source>
                  <year>1975</year>
                  <volume>72</volume>
                  <fpage>2994</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.72.8.2994</pub-id>
                  <?supplied-pmid 1059088?>
                  <pub-id pub-id-type="pmid">1059088</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patrono</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Rocca</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Measurement of thromboxane biosynthesis in health and disease</article-title>
                  <source>Front Pharm</source>
                  <year>2019</year>
                  <volume>10</volume>
                  <fpage>1244</fpage>
                  <pub-id pub-id-type="doi">10.3389/fphar.2019.01244</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Group</surname>
                      <given-names>ASC</given-names>
                    </name>
                    <name>
                      <surname>Bowman</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Mafham</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Wallendszus</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Stevens</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Buck</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effects of aspirin for primary prevention in persons with diabetes mellitus</article-title>
                  <source>N Engl J Med</source>
                  <year>2018</year>
                  <volume>379</volume>
                  <fpage>1529</fpage>
                  <lpage>39</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1804988</pub-id>
                  <pub-id pub-id-type="pmid">30146931</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Landolfi</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Marchioli</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kutti</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gisslinger</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Tognoni</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Patrono</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy and safety of low-dose aspirin in polycythemia vera</article-title>
                  <source>N Engl J Med</source>
                  <year>2004</year>
                  <volume>350</volume>
                  <fpage>114</fpage>
                  <lpage>24</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa035572</pub-id>
                  <?supplied-pmid 14711910?>
                  <pub-id pub-id-type="pmid">14711910</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rade</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Barton</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>Vasan</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Kronsberg</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Xanthakis</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Keaney</surname>
                      <given-names>JF</given-names>
                      <suffix>Jr.</suffix>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Association of thromboxane generation with survival in aspirin users and nonusers</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2022</year>
                  <volume>80</volume>
                  <fpage>233</fpage>
                  <lpage>50</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jacc.2022.04.034</pub-id>
                  <?supplied-pmid 35660296?>
                  <pub-id pub-id-type="pmid">35660296</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Coyle</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Cafferty</surname>
                      <given-names>FH</given-names>
                    </name>
                    <name>
                      <surname>Rowley</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>MacKenzie</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Berkman</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Gupta</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours</article-title>
                  <source>Contemp Clin Trials</source>
                  <year>2016</year>
                  <volume>51</volume>
                  <fpage>56</fpage>
                  <lpage>64</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cct.2016.10.004</pub-id>
                  <?supplied-pmid 27777129?>
                  <pub-id pub-id-type="pmid">27777129</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pagliaccia</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Habib</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Pitocco</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Petrucci</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Zaccardi</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Di Stasio</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Stability of urinary thromboxane A2 metabolites and adaptation of the extraction method to small urine volume</article-title>
                  <source>Clin Lab</source>
                  <year>2014</year>
                  <volume>60</volume>
                  <fpage>105</fpage>
                  <lpage>11</lpage>
                  <pub-id pub-id-type="doi">10.7754/Clin.Lab.2013.121238</pub-id>
                  <?supplied-pmid 24600983?>
                  <pub-id pub-id-type="pmid">24600983</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lellouche</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Fradin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Fitzgerald</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Maclouf</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin</article-title>
                  <source>Prostaglandins.</source>
                  <year>1990</year>
                  <volume>40</volume>
                  <fpage>297</fpage>
                  <lpage>310</lpage>
                  <pub-id pub-id-type="doi">10.1016/0090-6980(90)90017-P</pub-id>
                  <?supplied-pmid 2247619?>
                  <pub-id pub-id-type="pmid">2247619</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pradelles</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Grassi</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Maclouf</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay</article-title>
                  <source>Anal Chem</source>
                  <year>1985</year>
                  <volume>57</volume>
                  <fpage>1170</fpage>
                  <lpage>3</lpage>
                  <pub-id pub-id-type="doi">10.1021/ac00284a003</pub-id>
                  <?supplied-pmid 3898913?>
                  <pub-id pub-id-type="pmid">3898913</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Olson</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Kickler</surname>
                      <given-names>TS</given-names>
                    </name>
                    <name>
                      <surname>Lawson</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>McLean</surname>
                      <given-names>RC</given-names>
                    </name>
                    <name>
                      <surname>Jani</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>FitzGerald</surname>
                      <given-names>GA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk</article-title>
                  <source>J Thromb Haemost</source>
                  <year>2012</year>
                  <volume>10</volume>
                  <fpage>2462</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1111/jth.12026</pub-id>
                  <?supplied-pmid 23072449?>
                  <pub-id pub-id-type="pmid">23072449</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Joharatnam-Hogan</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Cafferty</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Hubner</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Swinson</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Sothi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Gupta</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial</article-title>
                  <source>Lancet Gastroenterol Hepatol</source>
                  <year>2019</year>
                  <volume>4</volume>
                  <fpage>854</fpage>
                  <lpage>62</lpage>
                  <pub-id pub-id-type="doi">10.1016/S2468-1253(19)30289-4</pub-id>
                  <?supplied-pmid 31477558?>
                  <pub-id pub-id-type="pmid">31477558</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rocca</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Ciabattoni</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Tartaglione</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Cortelazzo</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Barbui</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Patrono</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Increased thromboxane biosynthesis in essential thrombocythemia</article-title>
                  <source>Thromb Haemost</source>
                  <year>1995</year>
                  <volume>74</volume>
                  <fpage>1225</fpage>
                  <lpage>30</lpage>
                  <pub-id pub-id-type="doi">10.1055/s-0038-1649916</pub-id>
                  <?supplied-pmid 8607099?>
                  <pub-id pub-id-type="pmid">8607099</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ciabattoni</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Porreca</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Di Febbo</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Di Iorio</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Paganelli</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Bucciarelli</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Determinants of platelet activation in Alzheimer’s disease</article-title>
                  <source>Neurobiol Aging</source>
                  <year>2007</year>
                  <volume>28</volume>
                  <fpage>336</fpage>
                  <lpage>42</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.12.011</pub-id>
                  <?supplied-pmid 16442186?>
                  <pub-id pub-id-type="pmid">16442186</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Petrucci</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Zaccardi</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Giaretta</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Cavalca</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Capristo</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Cardillo</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation</article-title>
                  <source>J Thromb Haemost</source>
                  <year>2019</year>
                  <volume>17</volume>
                  <fpage>885</fpage>
                  <lpage>95</lpage>
                  <pub-id pub-id-type="doi">10.1111/jth.14445</pub-id>
                  <?supplied-pmid 30933424?>
                  <pub-id pub-id-type="pmid">30933424</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patrignani</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Panara</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Tacconelli</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Seta</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Bucciarelli</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Ciabattoni</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers</article-title>
                  <source>Circulation.</source>
                  <year>2000</year>
                  <volume>102</volume>
                  <fpage>539</fpage>
                  <lpage>45</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.CIR.102.5.539</pub-id>
                  <?supplied-pmid 10920066?>
                  <pub-id pub-id-type="pmid">10920066</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Davi</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Guagnano</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Ciabattoni</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Basili</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Falco</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Marinopiccoli</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Platelet activation in obese women: role of inflammation and oxidant stress</article-title>
                  <source>J Am Med Assoc.</source>
                  <year>2002</year>
                  <volume>288</volume>
                  <fpage>2008</fpage>
                  <lpage>14</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.288.16.2008</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Davi</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Catalano</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Averna</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Notarbartolo</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Strano</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ciabattoni</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Thromboxane biosynthesis and platelet function in type II diabetes mellitus</article-title>
                  <source>N Engl J Med</source>
                  <year>1990</year>
                  <volume>322</volume>
                  <fpage>1769</fpage>
                  <lpage>74</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJM199006213222503</pub-id>
                  <?supplied-pmid 2345567?>
                  <pub-id pub-id-type="pmid">2345567</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ballerini</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Contursi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bruno</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mucci</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tacconelli</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Patrignani</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Inflammation and cancer: from the development of personalized indicators to novel therapeutic strategies</article-title>
                  <source>Front Pharm</source>
                  <year>2022</year>
                  <volume>13</volume>
                  <fpage>838079</fpage>
                  <pub-id pub-id-type="doi">10.3389/fphar.2022.838079</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patrono</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Fifty years with aspirin and platelets</article-title>
                  <source>Br J Pharm</source>
                  <year>2023</year>
                  <volume>180</volume>
                  <fpage>25</fpage>
                  <lpage>43</lpage>
                  <pub-id pub-id-type="doi">10.1111/bph.15966</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ferroni</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Santilli</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Cavaliere</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Simeone</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Costarelli</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Liani</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Oxidant stress as a major determinant of platelet activation in invasive breast cancer</article-title>
                  <source>Int J Cancer</source>
                  <year>2017</year>
                  <volume>140</volume>
                  <fpage>696</fpage>
                  <lpage>704</lpage>
                  <pub-id pub-id-type="doi">10.1002/ijc.30488</pub-id>
                  <?supplied-pmid 27784132?>
                  <pub-id pub-id-type="pmid">27784132</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kiely</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Milne</surname>
                      <given-names>GL</given-names>
                    </name>
                    <name>
                      <surname>Minas</surname>
                      <given-names>TZ</given-names>
                    </name>
                    <name>
                      <surname>Dorsey</surname>
                      <given-names>TH</given-names>
                    </name>
                    <name>
                      <surname>Tang</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Urinary thromboxane B2 and lethal prostate cancer in African American men</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2022</year>
                  <volume>114</volume>
                  <fpage>123</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/djab129</pub-id>
                  <?supplied-pmid 34264335?>
                  <pub-id pub-id-type="pmid">34264335</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patrignani</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Filabozzi</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Patrono</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects</article-title>
                  <source>J Clin Invest</source>
                  <year>1982</year>
                  <volume>69</volume>
                  <fpage>1366</fpage>
                  <lpage>72</lpage>
                  <pub-id pub-id-type="doi">10.1172/JCI110576</pub-id>
                  <?supplied-pmid 7045161?>
                  <pub-id pub-id-type="pmid">7045161</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patrono</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Ciabattoni</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Remuzzi</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Gotti</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bombardieri</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Di Munno</surname>
                      <given-names>O</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus</article-title>
                  <source>J Clin Invest</source>
                  <year>1985</year>
                  <volume>76</volume>
                  <fpage>1011</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1172/JCI112053</pub-id>
                  <?supplied-pmid 3900132?>
                  <pub-id pub-id-type="pmid">3900132</pub-id>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patrignani</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Sacco</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Sostres</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Bruno</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Dovizio</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Piazuelo</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer</article-title>
                  <source>Clin Pharm Ther</source>
                  <year>2017</year>
                  <volume>102</volume>
                  <fpage>52</fpage>
                  <lpage>61</lpage>
                  <pub-id pub-id-type="doi">10.1002/cpt.639</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patrono</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Ciabattoni</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Patrignani</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Pugliese</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Filabozzi</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Catella</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clinical pharmacology of platelet cyclooxygenase inhibition</article-title>
                  <source>Circulation.</source>
                  <year>1985</year>
                  <volume>72</volume>
                  <fpage>1177</fpage>
                  <lpage>84</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.CIR.72.6.1177</pub-id>
                  <?supplied-pmid 3933848?>
                  <pub-id pub-id-type="pmid">3933848</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Santilli</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Rocca</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>De Cristofaro</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Lattanzio</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Pietrangelo</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Habib</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”</article-title>
                  <source>J Am Coll Cardiol</source>
                  <year>2009</year>
                  <volume>53</volume>
                  <fpage>667</fpage>
                  <lpage>77</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jacc.2008.10.047</pub-id>
                  <?supplied-pmid 19232899?>
                  <pub-id pub-id-type="pmid">19232899</pub-id>
                </element-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zaccardi</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Rizzi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Petrucci</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Ciaffardini</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Tanese</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Pagliaccia</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>In vivo platelet activation and aspirin responsiveness in type 1 diabetes</article-title>
                  <source>Diabetes.</source>
                  <year>2016</year>
                  <volume>65</volume>
                  <fpage>503</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.2337/db15-0936</pub-id>
                  <?supplied-pmid 26470782?>
                  <pub-id pub-id-type="pmid">26470782</pub-id>
                </element-citation>
              </ref>
              <ref id="CR57">
                <label>57.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Elisia</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Lam</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Cho</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Hay</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>MY</given-names>
                    </name>
                    <name>
                      <surname>Yeung</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The effect of smoking on chronic inflammation, immune function and blood cell composition</article-title>
                  <source>Sci Rep</source>
                  <year>2020</year>
                  <volume>10</volume>
                  <fpage>19480</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41598-020-76556-7</pub-id>
                  <?supplied-pmid 33173057?>
                  <pub-id pub-id-type="pmid">33173057</pub-id>
                </element-citation>
              </ref>
              <ref id="CR58">
                <label>58.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Giannakeas</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Narod</surname>
                      <given-names>SA</given-names>
                    </name>
                  </person-group>
                  <article-title>Incidence of cancer among adults with thrombocytosis in Ontario, Canada</article-title>
                  <source>JAMA Netw Open</source>
                  <year>2021</year>
                  <volume>4</volume>
                  <fpage>e2120633</fpage>
                  <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.20633</pub-id>
                  <?supplied-pmid 34383058?>
                  <pub-id pub-id-type="pmid">34383058</pub-id>
                </element-citation>
              </ref>
              <ref id="CR59">
                <label>59.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mounce</surname>
                      <given-names>LT</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Bailey</surname>
                      <given-names>SE</given-names>
                    </name>
                  </person-group>
                  <article-title>Cancer incidence following a high-normal platelet count: cohort study using electronic healthcare records from English primary care</article-title>
                  <source>Br J Gen Pr</source>
                  <year>2020</year>
                  <volume>70</volume>
                  <fpage>e622</fpage>
                  <lpage>e8</lpage>
                  <pub-id pub-id-type="doi">10.3399/bjgp20X710957</pub-id>
                </element-citation>
              </ref>
              <ref id="CR60">
                <label>60.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bailey</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Ukoumunne</surname>
                      <given-names>OC</given-names>
                    </name>
                    <name>
                      <surname>Shephard</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data</article-title>
                  <source>Br J Gen Pr</source>
                  <year>2017</year>
                  <volume>67</volume>
                  <fpage>e405</fpage>
                  <lpage>e13</lpage>
                  <pub-id pub-id-type="doi">10.3399/bjgp17X691109</pub-id>
                </element-citation>
              </ref>
              <ref id="CR61">
                <label>61.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sylman</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Mitrugno</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Tormoen</surname>
                      <given-names>GW</given-names>
                    </name>
                    <name>
                      <surname>Wagner</surname>
                      <given-names>TH</given-names>
                    </name>
                    <name>
                      <surname>Mallick</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>McCarty</surname>
                      <given-names>OJT</given-names>
                    </name>
                  </person-group>
                  <article-title>Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer</article-title>
                  <source>Converg Sci Phys Oncol</source>
                  <year>2017</year>
                  <volume>3</volume>
                  <fpage>023001</fpage>
                  <pub-id pub-id-type="doi">10.1088/2057-1739/aa6c05</pub-id>
                  <?supplied-pmid 29081989?>
                  <pub-id pub-id-type="pmid">29081989</pub-id>
                </element-citation>
              </ref>
              <ref id="CR62">
                <label>62.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Drew</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Cao</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>AT</given-names>
                    </name>
                  </person-group>
                  <article-title>Aspirin and colorectal cancer: the promise of precision chemoprevention</article-title>
                  <source>Nat Rev Cancer</source>
                  <year>2016</year>
                  <volume>16</volume>
                  <fpage>173</fpage>
                  <lpage>86</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrc.2016.4</pub-id>
                  <?supplied-pmid 26868177?>
                  <pub-id pub-id-type="pmid">26868177</pub-id>
                </element-citation>
              </ref>
              <ref id="CR63">
                <label>63.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sankaranarayanan</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kumar</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Altinoz</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Bhat</surname>
                      <given-names>GJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Mechanisms of colorectal cancer prevention by aspirin—a literature review and perspective on the role of COX-dependent and -independent pathways</article-title>
                  <source>Int J Mol Sci</source>
                  <year>2020</year>
                  <volume>21</volume>
                  <fpage>9018</fpage>
                  <pub-id pub-id-type="doi">10.3390/ijms21239018</pub-id>
                  <?supplied-pmid 33260951?>
                  <pub-id pub-id-type="pmid">33260951</pub-id>
                </element-citation>
              </ref>
              <ref id="CR64">
                <label>64.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patrono</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Ciabattoni</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Pinca</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Pugliese</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Castrucci</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>De Salvo</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects</article-title>
                  <source>Thromb Res</source>
                  <year>1980</year>
                  <volume>17</volume>
                  <fpage>317</fpage>
                  <lpage>27</lpage>
                  <pub-id pub-id-type="doi">10.1016/0049-3848(80)90066-3</pub-id>
                  <?supplied-pmid 7368167?>
                  <pub-id pub-id-type="pmid">7368167</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
